Abstract

Juvenile rheumatoid arthritis (JRA) (JA) has been the diagnostic label applied to any child whose arthritis is of unknown origin, begins under age 16, and persists for a minimum of 6 weeks.1,2 Arthritis is defined as swelling or both pain and limitation of motion in at least one joint. “Unknown origin” means that the physician has considered and excluded all other diseases, both common and unusual, that may cause or be associated with arthritis (Table 3.1). These “classification” criteria, adopted by a panel of experts (the JRA Criteria Subcommittee of the American Rheumatism Association—ARA, now the American College of Rheumatology—ACR), were extraordinarily successful in helping physicians distinguish arthritic disorders from other disorders in childhood. After 5 years, only 3% of children diagnosed as JRA by these criteria turned out to have some other disease. Interest in childhood arthritis was stimulated by publication of these criteria, and they helped to bring about the end of an era in which children with arthritis were frequently misdiagnosed and subjected to long hospitalizations, unnecessary surgery, harmful immobilization, and inadequate or inappropriate drug therapy.

Keywords

Rheumatoid Arthritis Ankylose Spondylitis Disseminate Intravascular Coagulation Juvenile Rheumatoid Arthritis Juvenile Chronic Arthritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    JRA Criteria Subcommittee. Criteria for classification of juvenile rheumatoid arthritis. Bull Rheum Dis 25: 712–719, 1973.Google Scholar
  2. 2.
    Cassidy JT, Levinson JE, Brewer EJ Jr: The development of classification criteria for children with juvenile rheumatoid arthritis. Bull Rheum Dis 38, 6: 1–7, 1989.PubMedGoogle Scholar
  3. 3.
    Calabro JJ, Marchesano JM: The early natural history of juvenile rheumatoid arthritis. Med Clin North Am 52: 567–591, 1968.PubMedGoogle Scholar
  4. 4.
    Schaller JG, Wedgwood RJ: Juvenile rheumatoid arthritis: A review. Pediatrics 50: 940–953, 1972.PubMedGoogle Scholar
  5. 5.
    Schaller JG: Juvenile rheumatoid arthritis. Arthritis Rheum 20: 165–170, 1977.PubMedGoogle Scholar
  6. 6.
    Stillman JS, Barry PE: Juvenile rheumatoid arthritis. Arthritis Rheum 20: 171–175, 1977.PubMedGoogle Scholar
  7. 7.
    Fink CW: Patients with JRA: A clinical study. Arthritis Rheum 20: 183–184, 1977.Google Scholar
  8. 8.
    Hanson V, Kornreich HK, Bernstein B, et al.: Three subtypes of juvenile rheumatoid arthritis. Arthritis Rheum 20: 184–186, 1977.Google Scholar
  9. 9.
    Levinson JE, Balz GP, Hess EV: Report of studies on juvenile arthritis. Arthritis Rheum 20: 189–190, 1977.Google Scholar
  10. 10.
    Suciu-Foca N, Jacobs JC, Khan R, et al.: Predisposition to juvenile arthritis: genetic aspects. In Moore T(ed.) Report of the Ross Conference on Pediatric Research. Xanadu, Bahamas, December 3, 1979, Ross Laboratories, Columbus, OH, 1981 pp. 72–75.Google Scholar
  11. 11.
    Baum J, Baum ER: Classics from medical literature: George Frederick Still and his account of childhood arthritis—a reappraisal (with replication of the original monograph On a Form of Chronic Joint Disease in Children). Am J Dis Child 132: 192–200, 1978.PubMedGoogle Scholar
  12. 12.
    Green WT: Monarticular and pauciarticular arthritis in children. JAMA 115: 2023–2024, 1940.Google Scholar
  13. 13.
    Brewer EJ, Bass J, Baum J, et al.: Current proposed revision of JRA criteria. Arthritis Rheum 20: 195–199, 1977.PubMedGoogle Scholar
  14. 14.
    Cassidy JT, Levinson JE, Bass JC, et al.: A study of Classification Criteria for a Diagnosis of Juvenile Rheumatoid Arthritis. Arthritis Rheum 29: 274–281, 1986.PubMedGoogle Scholar
  15. 15.
    Bywaters EGL: Still’s disease in the adult. Ann Rheum Dis 30: 121–133, 1971.PubMedGoogle Scholar
  16. 16.
    Arnett FC, Edworthy SM, Bloch DA, et al.: The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis Rheum 31: 315–324, 1988.PubMedGoogle Scholar
  17. 17.
    Stastny P, Fink C: Different HLA-D associations in adult and juvenile rheumatoid arthritis. J Clin Invest 63: 124–130, 1979.PubMedGoogle Scholar
  18. 18.
    Glass D, Litvin D, Wallace K, et al.: Early onset pauciarticular juvenile rheumatoid arthritis associated with HLA DRw5, iritis, and antinuclear antibody. J Clin Invest 66: 426–429, 1980.PubMedGoogle Scholar
  19. 19.
    van Zeben D, Hazes JMW, Zwinderman AH, et al.: Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. Arthritis Rheum 34: 822–830, 1991.PubMedGoogle Scholar
  20. 20.
    Kunnamo I, Kallio P, Pelkonen P, Hovi T: Clinical signs and laboratory tests in the differential diagonsis of arthritis in children. Am J Dis Child 141: 34–40, 1987.PubMedGoogle Scholar
  21. 21.
    Giannini EH, Brewer EJ: Poor correlation between the erythrocyte sedimentation rate and clinical activity in juvenile rheumatoid arthritis. Clin Rheumatol 6: 197–201, 1987.PubMedGoogle Scholar
  22. 21a.
    Schwarz-Eywill M, Heilig B, Bauer H, et al.: Evaluation of serum ferritin as a marker for adult Still’s disease activity. Ann Rheum Dis 51: 683–685, 1992.PubMedGoogle Scholar
  23. 22.
    Eichenfield AH, Athreya BH, Doughty RA, Cebul RD: Utility of rheumatoid factor in the diagonsis of juvenile rheumatoid arthritis. Pediatrics 78: 480–484, 1986.PubMedGoogle Scholar
  24. 23.
    Moore TL, Osborn TG, Weiss TD, et al.: Autoantibodies in juvenile arthritis. Semin Arthritis Rheum 13: 329–336, 1984.PubMedGoogle Scholar
  25. 24.
    Schaller JG, Johnson GD, Holborow EJ, et al.: The association of antinuclear antibodies with the chronic iridocyclitis of juvenile rheumatoid arthritis (Still’s disease). Arthritis Rheum 17: 409–416, 1974.PubMedGoogle Scholar
  26. 25.
    Monestier M, Losman JA, Fasy TM, et al.: Antihistone antibodies in antinuclear antibody-positive juvenile arthritis. Arthritis Rheum 33: 1836–1841, 1990.PubMedGoogle Scholar
  27. 26.
    Leak AM: Autoantibody profile in juvenile chronic arthritis. Ann Rheum Dis 47: 178–182, 1988.PubMedGoogle Scholar
  28. 27.
    Bergroth V, Konttinen YT, Pelkonen P, et al.: Synovial fluid lymphocytes in different subtypes of juvenile rheumatoid arthritis. Arthritis Rheum 31: 780–783, 1988.PubMedGoogle Scholar
  29. 28.
    Burdette S, Schwartz RS: Current concepts: immunology idiotypes and idiotypic networks. N. Eng J Med 317: 219–224, 1987.Google Scholar
  30. 29.
    Key LL Jr, Hoch S, Cairns L, et al.: Monocyte bone degradation: in vitro analysis of monocyte activity in patients with juvenile rheumatoid arthritis. J Pediatr 108: 405–409, 1986.PubMedGoogle Scholar
  31. 30.
    Pauls JD, Silverman E, Laxer RM, Fritzler MJ: Antibodies to histones Hl and H5 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum 32: 877–83, 1989.PubMedGoogle Scholar
  32. 31.
    Moore TL, Osborn TG, Dorner RW: Cross-reactive antiidiotypic antibodies against human rheumatoid factors from patients with juvenile rheumatoid arthritis. Arthritis Rheum 32: 699–705, 1989.PubMedGoogle Scholar
  33. 32.
    Tsokos GC, Inghirami G, Pillemer SR, et al.: Immunoregulatory aberrations in patients with polyarticular juvenile rheumatoid arthritis. Clin Immunol Immunopathol 47: 62–74, 1988.PubMedGoogle Scholar
  34. 33.
    Miller JJ III, Olds LC, Silverman ED, et al.: Different patterns of C3 and C4 activation in the varied types of juvenile arthritis. Pediatr Res 20: 1332–1337, 1986.PubMedGoogle Scholar
  35. 34.
    Silverman ED, Somma Catherine, Khan MM, et al.: Abnormal T suppressor cell function in juvenile rheumatoid arthritis. Arthritis Rheum 33: 205–211, 1990.PubMedGoogle Scholar
  36. 35.
    Moore TL, Osborn TG, Dorner RW: 19S IgM Rheumatoid factor-7S IgG rheumatoid factor immune complexes isolated in sera of patients with juvenile rheumatoid arthritis. Pediatr Res 20: 977–981, 1986.PubMedGoogle Scholar
  37. 36.
    Goldenberg DL: Infectious arthritis complicating rheumatoid arthritis and other chronic rheumatic disorders. Arthritis Rheum 32: 496–502, 1989.PubMedGoogle Scholar
  38. 37.
    Baldassare AR, Chano F, Zuckner J: Markedly raised synovial fluid leucocyte counts not associated with infectious arthritis in children. Ann Rheum Dis 37: 404–409, 1978.PubMedGoogle Scholar
  39. 38.
    Jacobs JC, Philips PE, Johnston AD: Needle biopsy of the synovium of children. Pediatrics 57: 696–701, 1976.PubMedGoogle Scholar
  40. 39.
    Sherman MS: The non-specificity of synovial reactions. Bull Hosp Joint Dis 12: 110–125, 1951.PubMedGoogle Scholar
  41. 40.
    Wynne-Roberts CR: Anderson CH, Turano AM, Baron M. Light and electronmircoscopic findings of juvenile rheumatoid arthritis synovium: comparison with normal juvenile synovium. Semin Arthritis Rheum 7: 287–302, 1978.PubMedGoogle Scholar
  42. 41.
    Konttinen YT, Bergroth V, Kunnamo I, Haapasaari J: The value of biopsy in patients with monarticular juvenile rheumatoid arthritis of recent onset. Arthritis Rheum 29: 47–53, 1986.PubMedGoogle Scholar
  43. 42.
    Grokoest AW, Snyder AI, Schlaeger R: Juvenile Rheumatoid Arthritis, Little, Brown, Boston, 1962.Google Scholar
  44. 43.
    Martel W, Holt JF, Cassidy JT: Roentgenologic manifestations of juvenile rheumatoid arthritis. Am J Roentgenol Radium Ther Nucl Med 88: 400–423, 1962.PubMedGoogle Scholar
  45. 44.
    Poznanski AK, Glass RBJ, Feinstein KA, et al.: Magnetic resonance imaging in juvenile rheumatoid arthritis. Int Pediatr 3: 304–310, 1988.Google Scholar
  46. 45.
    Senac MO, Deutsch D, Bernstein BH, et al.: MR Imaging in juvenile rheumatoid arthritis. AJR 150: 873–878, 1988.PubMedGoogle Scholar
  47. 46.
    Stoller DW, Genant HK: Magnetic resonance imaging of the knee and hip. Arthritis Rheum 33: 441–449, 1990.PubMedGoogle Scholar
  48. 47.
    Sartoris DJ: Magnetic resonance imaging of the musculoskeletal system. J Musculoskel Med 7: 29–45, 1990.Google Scholar
  49. 48.
    Towner SR, Michael CJ Jr, O’Fallon WM, Nelson AM: The epidemiology of juvenile arthritis in Rochester, Minnesota 1960–1979. Arthritis Rheum 26: 1208–1213, 1983.PubMedGoogle Scholar
  50. 49.
    Kunnamo I, Kallio P, Pelkonen P: Incidence of arthritis in urban Finnish children: A prospective study. Arthritis Rheum 29: 1232–1238, 1986.PubMedGoogle Scholar
  51. 50.
    Petty RE: Epidemiology of juvenile rheumatoid arthritis. In Miller JJ III (ed.) Juvenile Rheumatoid Arthritis. PSG, Littleton, MA 1979, pp. 11–18.Google Scholar
  52. 51.
    Gewanter HL, Roghmann KJ, Baum J: The prevalence of juvenile arthritis Arthritis Rheum 26: 599–603, 1983.Google Scholar
  53. 52.
    Laaksonen A: A prognostic study of juvenile rheumatoid arthritis. Acta Paediatr Scand [Suppl.] 166, 1966.Google Scholar
  54. 53.
    Kredich DW: Polyarticularjuvenile rheumatoid arthritis. In Miller JJ III (ed.) Juvenile Rheumatoid Arthritis. PSG, Littleton, MA, 1977, pp. 121–134.Google Scholar
  55. 54.
    Clemens LE, Albert E, Ansell BM: Sibling pairs affected by chronic arthritis of children: Evidence for a genetic predisposition. J Rheumatol 12: 108–113, 1985.PubMedGoogle Scholar
  56. 55.
    Nepom BS, Malhortra U, Schwarz DA, et al.: HLA and T Cell receptor polymorphisms in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 34: 1260–1267, 1991.PubMedGoogle Scholar
  57. 56.
    Aaron S, Fraser PA, Jackson JM, et al.: Sex ratio and sibship size in juvenile rheumatoid arthritis kindreds. Arthritis Rheum 28: 753–758, 1985.PubMedGoogle Scholar
  58. 57.
    van Kerckhove C, Glass DN: The immunoglobulin supergene family and the polygenic nature of inherited predisposition to rheumatic disease. Arthritis Rheum 30: 951–953, 1987.PubMedGoogle Scholar
  59. 58.
    Albert ED, Ansell BM: Immunogenetics of juvenile chronic arthritis. Scand J Rheumatol Suppl. 66: 85–91, 1987.PubMedGoogle Scholar
  60. 59.
    Calabro JJ, Marchesano JM: Fever associated with juvenile rheumatoid arthritis. N Engl J Med 276: 11–18, 1967.PubMedGoogle Scholar
  61. 60.
    Pizzo PA, Lovejoy FH Jr, Smith DH: Prolonged fever in children: Review of 100 cases. Pediatrics 55: 468–473, 1975.PubMedGoogle Scholar
  62. 61.
    Lohr JA, Hendley JO: Prolonged fever of unknown origin. Clin Pediatr 16: 768–773, 1977.Google Scholar
  63. 62.
    McClung HJ: Prolonged fever of unknown origin in children. Am J Dis Child 124: 544–550, 1972.PubMedGoogle Scholar
  64. 63.
    Schaller J: Arthritis as a presenting manifestation of malignancy in children. J Pediatr 81: 793–797, 1972.PubMedGoogle Scholar
  65. 64.
    Estrada R, Schaeffer H, Rosenfeld W, et al.: Anhidrotic ectodermal dysplasia. Fever in a neonate. NYS J Med 81: 1791–1793, 1981.Google Scholar
  66. 65.
    Case records of the Massachusetts General Hospital. CASE No. 22:1991. N Eng J Med 324: 1575–1584, 1991.Google Scholar
  67. 66.
    Lake AM, Oski FA: Peripheral lymphadenopathy in childhood. Am J Dis Child 132: 357–359, 1978.PubMedGoogle Scholar
  68. 67.
    Sullivan DB, Cassidy JT, Petty RE: Pathogenic implications of age of onset in juvenile rheumatoid arthritis. Arthritis Rheum 18: 251–254, 1975.PubMedGoogle Scholar
  69. 68.
    Ansell BM, Bywaters EGL: Rheumatoid arthritis (Still’s disease). Ped Clin North Am 10: 921–939, 1963.Google Scholar
  70. 69.
    Bujak JS, Aptekar RG, Decker JL, et al.: Juvenile rheumatoid arthritis presenting in the adult as fever of unknown origin. Medicine 52: 431–444, 1973.PubMedGoogle Scholar
  71. 70.
    Ohta A, Yamaguchi M, Kaneoka H, et al.: Adult Still’s Disease: review of 228 cases from the literature. J Rheumatol 14: 1139–1146, 1987.PubMedGoogle Scholar
  72. 71.
    Cush-JJ, Medsger TA Jr, Christy, WC: Adult-onset Still’s disease. Clinical course and outcome. Arthritis Rheum 30: 186–194, 1987.PubMedGoogle Scholar
  73. 72.
    Reginato AJ, Schumacher HR Jr, Baker DG, et al.: Adult onset Still’s disease: experience in 23 patients and literature review with emphasis on organ failure. Semin Arthritis Rheum 17: 39–57, 1987.PubMedGoogle Scholar
  74. 73.
    Lindsley CB: Seasonal variation in systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 30: 838–839, 1987.PubMedGoogle Scholar
  75. 74.
    Ansell BM, Bywaters EGL: Diagnosis of “probable” Still’s disease and its outcome. Ann Rheum Dis 21: 253–262, 1962.PubMedGoogle Scholar
  76. 75.
    Isdale IC, Bywaters, EGL: The rash of rheumatiod arthritis and Still’s disease. Q J Med 25: 377–387, 1956.PubMedGoogle Scholar
  77. 76.
    Calabro JJ, Marchesano JM: Rash associated with juvenile rheumatoid arthritis. J Pediatr 72: 611–619, 1968.PubMedGoogle Scholar
  78. 77.
    de Benedetti F, Massa M, Robbioni P, et al.: Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34: 1158–1163, 1991.PubMedGoogle Scholar
  79. 78.
    Schlesinger BE, Forsyth CC, White RHR, et al.: Observations on the clinical course and treatment of one hundred cases of Still’s disease. Arch Dis Child 36: 65–76, 1961.PubMedGoogle Scholar
  80. 79.
    Calabro JJ, Burnstein SL, Staley HL: JRA posing as fever of unknown origin. Arthritis Rheum 20: 178–180, 1977.Google Scholar
  81. 79a.
    Schneider R, Lang BA, Reilly BJ, et al.: Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. J Pediatr 120: 200–5, 1992PubMedGoogle Scholar
  82. 80.
    Barber FA, Roach JW: Torticollis: A presentation of eosinophilic granuloma: A case report. Orthopedics 9: 1237–1239, 1986.PubMedGoogle Scholar
  83. 81.
    Steinberg GG: Osteomyelitis of the rib presenting as painful torticollis: Case report. J Bone Joint Surg 61-A: 614–616, 1979.Google Scholar
  84. 82.
    Schaller JG: The diversity ofJRA. Arthritis Rheum 20 (Suppl): 52–63, 1977.Google Scholar
  85. 83.
    Rachelefsky GS, Kar NC, Coulson A, et al.: Serum enzyme abnormalities in juvenile rheumatoid arthritis. Pediatrics 58: 730–736, 1976.PubMedGoogle Scholar
  86. 84.
    Halla JT, Koopman WJ, Fallahi S, et al.: Rheumatoid myositis. Clinical and histologic features and possible pathogenesis. Arthritis Rheum 27: 737–743, 1984.PubMedGoogle Scholar
  87. 85.
    Schaller JG, Beckwith B, Wedgwood RJ: Hepatic involvement in juvenile rheumatoid arthritis. J Pediatr 77: 203–209, 1970.PubMedGoogle Scholar
  88. 86.
    Brewer EJ, Giannini E, Person D: Juvenile Rheumatoid Arthritis 2nd edition, Saunders, Philadelphia, 1982.Google Scholar
  89. 87.
    Ohta A, Matsumoto Y, Ohta T, et al.: Still’s disease associated with necrotizing lymphadenitis (Kikuchi’s disease): Report of 3 cases. J Rheumatol 15:981–983, 1988 (see also: Correspondence: 17: 568–569, 1990 ).Google Scholar
  90. 88.
    Wang FM, Wertenbaker C, Behrens MM, Jacobs JC: Acquired Brown’s syndrome in children with juvenile rheumatoid arthritis. Ophthalmology 91: 23–26, 1984.PubMedGoogle Scholar
  91. 89.
    Yousefzadeh DK, Fishman PA: The triad of pneumonitis, pleuritis, and pericarditis in juvenile rheumatoid arthritis. Pediatr Radiol 8: 147–150, 1979.PubMedGoogle Scholar
  92. 90.
    Brewer E: Juvenile rheumatoid arthritis-cardiac involvement. Arthritis Rheum 20: 231–236, 1977.PubMedGoogle Scholar
  93. 91.
    Miller JJ III: Carditis in JRA. In Miller JJ III (ed.) Juvenile Rheumatoid Arthritis. PSG, Littleton, MA, 1979, pp. 165–173.Google Scholar
  94. 92.
    Yancey CL, Doughty RA, Cohlan BA, Athreya BH: Pericarditis and cardiac tamponade in juvenile rheumatoid arthritis. Pediatrics 68: 369–373, 1981.PubMedGoogle Scholar
  95. 93.
    Lietman PS, Bywaters EGL: Pericarditis in juvenile rheumatoid arthritis. Pediatrics 32: 855–860, 1963.PubMedGoogle Scholar
  96. 94.
    Svantesson H, Bjorkhem G, Elborgh R: Cardiac involvement in juvenile rheumatoid arthritis: a follow-up study. Acta Paediatr Scand 72: 345–350, 1983.PubMedGoogle Scholar
  97. 95.
    Smith WG: Coxsackie B myopericarditis in adults. Am Heart J 80: 34–46, 1970.PubMedGoogle Scholar
  98. 96.
    Tilzey AJ, Signy M, Banatvala JE: Persistent coxsackie B virus specific IgM response in patients with recurrent pericarditis. Lancet 1: 1491–1492, 1986.PubMedGoogle Scholar
  99. 97.
    Soutar CA: Unusual case of viral pericarditis. Lancet 1: 498, 1971.PubMedGoogle Scholar
  100. 98.
    Rahal JJ, Millian SJ, Noriega ER: Coxsackie virus and adenovirus infection: Association with acute febrile and juvenile rheumatoid arthritis. JAMA 235: 2496–2501, 1976.PubMedGoogle Scholar
  101. 99.
    Adler R, Takahashi M, Wright HT: Acute pericarditis associated with hepatitis B infection. Pediatrics 61: 716–719, 1978.PubMedGoogle Scholar
  102. 100.
    Wong KF, Chan JKC, Chan CH: Psittacosis-Associated hemophagocytic syndrome. Am J Med 91: 204–205, 1991.PubMedGoogle Scholar
  103. 101.
    Morris JA, Adamson AR, Holt PJL, Dayson J: Still’s disease and the virus-associated haemophagocytic syndrome. Ann Rheum Dis 44: 349–353, 1985.PubMedGoogle Scholar
  104. 102.
    Heaton DC, Moller PW: Case report: Still’s disease associated with Coxsackie infection and haemophagocytic syndrome. Ann Rheum Dis 44: 341–344, 1985.PubMedGoogle Scholar
  105. 103.
    Hurst NP, Martkynoga AG, Nuki G, et al.: Coxsackie B infection and arthritis. Br Med J 286: 580, 1983.Google Scholar
  106. 104.
    Roberts-Thomson PJ, Ahern MJ, Southwood TR, et al.: Adult onset Still’s Disease or Coxsackie Polyarthritis? Aust NZ J Med 16: 509–511, 1986.Google Scholar
  107. 105.
    Fraser KJ, Clarris BJ, Muirden KD, et al.: A persistent adenovirs type 1 infection in synovial tissue from an immunodeficient patient with chronic, rheumatoid-like polyarthritis. Arthritis Rheum 28: 455–458, 1985.PubMedGoogle Scholar
  108. 106.
    Denman AM: A viral aetiology for juvenile chronic arthritis. J Rheum 27: 169–175, 1988.Google Scholar
  109. 107.
    Delgado EA, Petty RE, Malleson PN, et al.: Aortic valve insufficiency and coronary artery narrowing in a child with polyarticular juvenile rheumatoid arthritis. J Rheumatol 15: 144–147, 1988.PubMedGoogle Scholar
  110. 108.
    Singleton EB, Wagner ML: Radiographic Atlas of Pulmonary Abnormalities in Children. Saunders, Philadelphia, 1971, p. 240.Google Scholar
  111. 109.
    Athreya BH, Doughty RA, Bookspan M, et al.: Pulmonary manifestations of juvenile rheumatoid arthritis. A report of eight cases and review. Clin Chest Med 1: 361–374, 1980.PubMedGoogle Scholar
  112. 110.
    Lovell D, Lindsley C, Langston C: Lymphoid interstitial pneumonia in juvenile rheumatoid arthritis. J Pediatr 105: 947–950, 1984.PubMedGoogle Scholar
  113. 111.
    O’Brodovich HM, Way RC, Andrew M, Dent PB: Nonivasive diagnosis of pulmonary hemorrhage in rheumatoid arthritis. Pediatrics 72: 720–723, 1983.PubMedGoogle Scholar
  114. 112.
    WagenerJS, Taussig LM, DeBenedetti G, et al.: Pulmonary function in juvenile rheumatoid arthritis. J Pediatr 99: 108–110, 1981.PubMedGoogle Scholar
  115. 113.
    Padeh S, Laxer RM, Silver MM, Silverman ED: Primary pulmonary hypertension in a patient with systemic-onset juvenile arthritis. Arthritis Rheum 34: 1575–1679, 1991.PubMedGoogle Scholar
  116. 114.
    Jacobs JC, Hui RM: Cricoarytenoid arthritis and airway obstruction in juvenile rheumatoid arthritis. Pediatrics 59: 292–294, 1977.PubMedGoogle Scholar
  117. 115.
    Jan JE, Hill RH, Low MD: Cerebral complications in juvenile rheumatoid arthritis. Can Med Assoc J 107: 623–625, 1972.PubMedGoogle Scholar
  118. 116.
    Sievers K, Nisshla M, Sievers UM: Cerebral vasculitis visualized by angiography in juvenile rheumatoid arthritis simulating brain tumor. Acta Rheum Scand 14: 222–232, 1968.PubMedGoogle Scholar
  119. 117.
    O’Connor D, Bernstein B, Hanson V, et al.: Disease of central nervous system in juvenile rheumatoid arthritis (JRA), abstracted. Arthritis Rheum 23: 727, 1980.Google Scholar
  120. 118.
    Anttila R: Renal involvement in juvenile rheumatoid arthritis. A clinical and histopathological study. Acta Paediatr Scand [Suppl.] 227, 1972.Google Scholar
  121. 119.
    Stapleton FB, Hanissian AS, Miller LA: Hypercalciuria in children with juvenile rheumatoid arthritis: association with hematuria. J Pediatr 107: 235–239, 1985.PubMedGoogle Scholar
  122. 120.
    Reed A, Haugen M, Pachman LM, Langman CB: Abnormalities in serum osteocalcin values in children with chronic rheumatic diseases. J Pediatr 116: 574–580, 1990.PubMedGoogle Scholar
  123. 121.
    Levy M, Prieur A-M, Gubler M-C, et al.: Renal involvement in juvenile chronic arthritis: clinical and pathologic features. Am J Kidney Dis 9: 138–146, 1987.PubMedGoogle Scholar
  124. 122.
    Malleson PN, Lockitch G, MacKinnon M, et al.: Renal disease in chronic arthritis of childhood. A study of urinary N-acetyl-8-glucosaminidase and B2microglobulin excretion. Arthritis Rheum 33: 1560–1566, 1990.PubMedGoogle Scholar
  125. 123.
    Schnitzer TJ, Ansell BM: Amyloidosis in juvenile chronic polyarthritis. Arthritis Rheum 20: 245–252, 1977.PubMedGoogle Scholar
  126. 124.
    Youyfouka O, David J, Ansell BA, et al.: Mortality and morbidity of a cohort of juvenile arthritis patients with amyloidosis. Arthritis Rheum 335: 144, 1990.Google Scholar
  127. 125.
    Baum J. Gutowska G: Death in juvenile rheumatoid arthritis. Arthritis Rheum 20: 253–255, 1977.Google Scholar
  128. 126.
    Duston MA, Skinner M, Shirahama T, Cohen AS: Diagnosis of amyloidosis by abdominal fat aspiration: analysis of four years’ experience. Am J Med 82: 412–414, 1987.PubMedGoogle Scholar
  129. 127.
    Cohen AS, Skinner M: New frontiers in the study of amyloidosis. N Engl J Med 323: 542–543, 1990.PubMedGoogle Scholar
  130. 127a.
    Hawkins PN, Richardson S, David J, et al.: Monitoring amyloidosis in juvenile rheumatoid arthritis with serum amyloid P component scintography. Arthritis Rheum 34: 5124, 1991.Google Scholar
  131. 128.
    Rostropowicz-Denisiewicz K, Romicka AM, Berkan E, Luft S: The course of amyloidosis in juvenile chronic arthritis with immunoglobulin deficiency. Scand J Rheumatol. Suppl 67: 27–29, 1988.Google Scholar
  132. 129.
    Escalante A, Ehresmann GR, Quismorio FP Jr.: Regression of reactive systemic amyloidosis due to ankylosing spondylitis following the administration of colchicine. Arthritis Rheum 34: 920–922, 1991.PubMedGoogle Scholar
  133. 130.
    Gall EP, Goldberg M. Editorial. The safety of treating rheumatoid arthritis with aspirin and analgesic nephropathy in 1981: Which drug is responsible? JAMA 247: 63–65, 1982.PubMedGoogle Scholar
  134. 131.
    Wortmann DW, Kelsch RC, Kuhns L, et al.: Renal papillary necrosis in juvenile rheumatoid arthritis. J Pediatr 97: 37–40, 1980.PubMedGoogle Scholar
  135. 132.
    Allen RC, Petty RE, Lirenman DS, et al.: Renal papillary necrosis in children with chronic arthritis. Am J Dis Child 140:20–22, 1986 (see also editorial pp. 16–17).Google Scholar
  136. 133.
    Koerper MA, Stempel DA, Dallman PR: Anemia in patients with juvenile rheumatoid arthritis. J Pediatr 92: 930–933, 1980.Google Scholar
  137. 134.
    Gross SJ, Stuart MJ, Swender PT, et al.: Malabsorption of iron in children with iron deficeincy. J Pediatr 88: 795–799, 1976.PubMedGoogle Scholar
  138. 135.
    Vichinsky E: Anemia associated with rhenumatoid arthritis. J Pediatr 94: 678, 1979.PubMedGoogle Scholar
  139. 136.
    Hochbery MC, Arnold CM, Hogans BB, Spivak JL: Serum immunoreactive erythropoietin in rheumatoid arthritis: impaired response to anemia. Arthritis Rheum 31: 1318–1321, 1988.Google Scholar
  140. 137.
    Maury CPJ, Andersson LC, Teppo A-M, et al.: Mechanism of anaemia in rheumatoid arthritis: demonstration of raised interleukin 1 concentrations in anaemic patients and of interleukin 1 mediated suppression in normal erythropoiesis and proliferation of human erythroleukaemia (HEL) cells in vitro. Ann Rheum Dis 47: 972–978, 1988.PubMedGoogle Scholar
  141. 138.
    Dessypris EN, Baer MR, SergentJS, Krantz SB: Rheumatoid arthritis and pure red cell aplasia. Ann Intern Med 100: 202–206, 1984.PubMedGoogle Scholar
  142. 139.
    Rubin RN, Walker BK, Ballas SK, et al.: Erythroid aplasia in juvenile rheumatoid arthritis. Am J Dis Child 132: 760–762, 1978.PubMedGoogle Scholar
  143. 140.
    Glader BE: Evaluation of the hemolytic role of aspirin in glucose-6-phosphate dehydrogenase deficiency. J Pediatr 89: 1027–1028, 1976.PubMedGoogle Scholar
  144. 141.
    Craft AW, Eastham EJ, Bell JI, et al.: Serum ferritin in juvenile chronic polyarthritis. Ann Rheum Dis 36: 271–273, 1977.PubMedGoogle Scholar
  145. 142.
    Vreugdenhil G, Baltus CAM, Van Eijk HG, Swaak AJG: Anaemia of chronic disease: Diagnostic significance of erythrocyte and serological parameters in iron deficient rheumatoid arthritis patients. Br J Rheumatol 29: 105–110, 1990.PubMedGoogle Scholar
  146. 143.
    Johansson U, Portinsson S, Akesson A, et al.: Nutritional status in girls with juvenile rheumatoid arthritis. Hum Nutr Clin Nutr 40C: 57–67, 1985.Google Scholar
  147. 144.
    Herbert V: The nutritional anemias. Hosp Pract 15 (3): 65–89, 1980.PubMedGoogle Scholar
  148. 145.
    Winyard PG, Blake DR, Chirico S, et al.: Mechanism of exacerbation of rheumatoid synovitis by total-dose iron-dextran infusion: in-vivo demonstration of iron-promoted oxidant stress. Lancet 1:69–72, 1987 (see also correpondence p. 391).Google Scholar
  149. 146.
    Pincus T, Olsen NJ, Russell IJ, et al.: Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 89: 161–168, 1990.PubMedGoogle Scholar
  150. 146a.
    Fantini F, Gattinara M, Gerloni V, et al.: Severe anemia associated with systemic-onset juvenile rheumatoid arthritis successfully treated with recombinant human erythropoeitin: a pilot study. Arthritis Rheum 35: 724–726, 1992.PubMedGoogle Scholar
  151. 147.
    Kuhns JG, Swain LT: Distrubances of growth in chronic arthritis in children. Am J Dis Child 43: 1118–1133, 1932.Google Scholar
  152. 148.
    Coss JA Jr, Boots RH: Juvenile rheumatoid arthritis-a study of fifty-six cases with a note on skeletal changes. J Pediatr 29: 143–156, 1946.PubMedGoogle Scholar
  153. 149.
    Ansell BM, Bywaters EGL: Growth in Still’s disease. Ann Rheum Dis 15: 295–319, 1956.PubMedGoogle Scholar
  154. 150.
    Bernstein BH, Stobie D, Singsen BH, et al.: Growth retardation in juvenile rheumatoid arthritis (JRA). Arthritis Rheum 20: 212–216, 1977.PubMedGoogle Scholar
  155. 151.
    Bennett AE, Silverman ED, Miller JJ III, Hintz RL: Insulin-like growth factors I and II in children with systemic onset juvenile arthritis. J Rheumatol 15: 655–658, 1988.PubMedGoogle Scholar
  156. 152.
    Aitman TJ, Palmer RG, Loftus J, et al.: Serum IGF-I levels and growth failure in juvenile chronic arthritis. Clin Exp Rheumatol 7: 557–561, 1989.PubMedGoogle Scholar
  157. 153.
    Sadeghi-Nejad A, Seniro B: Adrenal function, growth and insulin in patients treated with corticoids on alternate days. Pediatrics 43: 277–283, 1969.PubMedGoogle Scholar
  158. 154.
    Davies UM, Ansell BM, Woo P: Growth retardation in juvenile chronic arthritis: effect of treatment with biosynthetic human growth hormone. Arthritis Rheum 33: S14, 1990.Google Scholar
  159. 155.
    Rappaport EB, Snoy P, Habig WH, Bright RW: Effects of exogenous growth hormone on growth plate cartilage in rats. Am J Dis Child 141: 497–501, 1987.PubMedGoogle Scholar
  160. 156.
    Loeb JN: Corticosteroids and growth. N Engl J Med 295: 547–552, 1976.PubMedGoogle Scholar
  161. 157.
    Ansell BM, Bywaters EGL: Alternate-day corticosteriod therapy in juvenile chronic polyarthritis. J Rheum 1: 176–186, 1974.PubMedGoogle Scholar
  162. 158.
    Wales JKH, Milner RDG: Variation in lower leg growth with alternate day steroid treatment. Arch Dis Child 63: 981–983, 1988.PubMedGoogle Scholar
  163. 159.
    Richards GE, Pachman LM, Green CC: Symptomatic hypothyroidism in children with collagen disease. J Pediatr 87: 82–84, 1975.PubMedGoogle Scholar
  164. 160.
    Collen RJ, Lippe BM, Kaplan SA: Primary ovarian failure, juvenile rheumatoid arthritis, and vitiligo. Am J Dis Child 133: 598–600, 1979.PubMedGoogle Scholar
  165. 161.
    Fisher M, Nussbaum M, Abrams CAL, et al.: Diabetes mellitus. Hashimoto’s, thyroiditis, and juvenile rheumatoid arthritis. Am J Dis Child 134: 93–94, 1980.PubMedGoogle Scholar
  166. 162.
    Pirani CL, Bennett GA: Rheumatoid arthritis: A report of three cases progressing from childhood and emphasizing certain systemic manifestations. Bull Hosp Joint Dis 12: 335–367, 1951.PubMedGoogle Scholar
  167. 163.
    Cabane J, Michon A, Ziza J-M, et al.: Comparison of long term evolution of adult onset and juvenile onset Still’s disease, both followed up for more than 10 years. Ann Rheum Dis 49: 283–285, 1990.PubMedGoogle Scholar
  168. 164.
    Bywaters EGL: Deaths in juvenile chronic polyarthritis. Arthritis Rheum 20: 256, 1977.Google Scholar
  169. 165.
    Bernstein B: Death in juvenile rheumatoid arthritis. Arthritis Rheum 20: 256–257, 1977.Google Scholar
  170. 166.
    Scott JP, Pachman LM, Gerber PS, et al.: Activation of coagulation in systemic JRA (S JRA). Arthritis Rheum 26: S57, 1983.Google Scholar
  171. 167.
    Mukamel M, Bernstein BH, Brik R, Lehman TJA: The prevalence of coagulation abormalities in juvenile rheumatoid arthritis. J Rheumatol 14: 1147–1149, 1987.PubMedGoogle Scholar
  172. 168.
    Sbarbaro JA, Bennett RM: Aspirin hepatotoxicity and disseminated intravascular coagulation. Ann Intern Med 86: 183–185, 1977.PubMedGoogle Scholar
  173. 169.
    Jacobs JC, Gorin LJ, Hanissian AS, Simon JL: Consumption coagulopathy after gold therapy for JRA. J Pediatr 105: 674–675, 1984.PubMedGoogle Scholar
  174. 170.
    Silverman ED, Miller JJ III, Bernstein B, Shafai T: Comsumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr 103: 872–876, 1983.PubMedGoogle Scholar
  175. 171.
    Pinedo HM, Van de Putte BA, Loeliger EA: Salicylate-induced consumption coagulopathy. Ann Rheum Dis 32: 66–68, 1973.PubMedGoogle Scholar
  176. 172.
    De Vere-Tyndall A, MacAuley D, Ansell BM: Disseminated intravascular coagulation complicating systemic juvenile chronic arthritis (“Still’s disease”). Clin Rheumatol 2: 415–418, 1983.PubMedGoogle Scholar
  177. 173.
    Kornreich H, Malouf NN, Hanson V: Acute hepatic dysfunction in juvenile rheumatoid arthritis. J Pediatr 79: 27–35, 1971.PubMedGoogle Scholar
  178. 174.
    Lipinski J, Meyer R, Kornetsky C, Cohen BM: Adult respiratory-distress syndrome in salicylate intoxication. Lancet 1: 1294–1295, 1979.Google Scholar
  179. 175.
    Case Records of the Massachusetts General Hospital: Case 23–1977. N Eng J Med 296: 1337–1346, 1977.Google Scholar
  180. 176.
    Merskey C: DIC: Identification and management. Hosp Pract pp. 83–94, December 1982.Google Scholar
  181. 177.
    Sherry DD, Kredich DW: Transient thrombocytopenia in systemic onsetjuvenile rheumatoid arthritis. Pediatrics 76: 600–603, 1985.PubMedGoogle Scholar
  182. 178.
    Hadchouel M, Prieur A-M, Griscelli C: Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 106: 561–566, 1985.PubMedGoogle Scholar
  183. 179.
    Levy J, Pettei MJ, Weitz JI: Dysfibrinogenemia in obstructive liver disease. J Pediatr Gastroenterol Nutr 6: 967–970, 1987.PubMedGoogle Scholar
  184. 180.
    Ohaska A, Saito K, Mori S, et al.: Clinicopathologic and therapeutic aspects of angioimmunoblastic lymphadenopathy-related lesions. Cancer 69: 1259–1267, 1992.Google Scholar
  185. 181.
    Steinberg AD, Seldin MF, Jaffe ES, et al.: Angioimmunoblastic lymphadenopathy with dysproteinemia. Ann Intern Med 108: 575–584, 1988.PubMedGoogle Scholar
  186. 182.
    Buchanan WW, Rooney RJ, Rennie JAN: Aspirin and the salicylates. Clin Rheum Dis 5: 499–539, 1979.Google Scholar
  187. 183.
    Levy G, Leonards JR: Urine pH and salicylate therapy. JAMA 217: 81, 1971.PubMedGoogle Scholar
  188. 184.
    Lanza FL, Royer GL Jr, Nelson RS: Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric coated aspirin on gastric and duodenal mucosa. N Engl J Med 303: 136–138, 1980.PubMedGoogle Scholar
  189. 185.
    Vane JR: Inhibitors of prostaglandin, prostacyclin and thromboxane synthesis. In Coceani F, Olley PJ (eds.) Advances in Prostaglandin Research, Vol. 4 Raven Press, New York, 1978, pp. 27–44.Google Scholar
  190. 186.
    Morley J, Bray MA, Gordon D: The action of anti-inflammatory drugs on the lymphocyte-macrophage axis. In Glynn LE, Schlumberger HD (eds.) Experimental Models of Chronic Inflammatory Disease. Springer-Verlag, Berlin, 1977, pp. 376–390.Google Scholar
  191. 187.
    Boardman PL, Hart FD: Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis. Br Med J 4: 264–268, 1967.PubMedGoogle Scholar
  192. 188.
    Ansell BM: Juvenile chronic arthritis. In Hart FD (ed.) Drug Treatment of the Rheumatic Diseases. Williams and Wilkins. Sydney, 1987, pp. 196–208.Google Scholar
  193. 189.
    Doughty RA, Giesecke L, Athreya B: Salicylate therapy in juvenile rheumatoid arthritis: dose, serum level, and toxicity. Am J Dis Child 134: 461–463, 1980.PubMedGoogle Scholar
  194. 190.
    Jacobs JC, Pesce M: Micro-measurement of plasma salicylate in arthritic children. Arthritis Rheum 21: 129–132, 1978.PubMedGoogle Scholar
  195. 191.
    Bardare M, Cislaghi GU, Mandelli M, et al.: Value of monitoring plasma salicylate levels in treating juvenile rheumatoid arthritis. Arch Dis Child 53: 381–385, 1978.PubMedGoogle Scholar
  196. 192.
    Levy G: Clinical pharmacokinetics of aspirin. Pediatrics 62: 867–872, 1978.PubMedGoogle Scholar
  197. 193.
    Graham GG, Champion GD, Day RD, et al.: Patterns of plasma concentrations and urinary excretion of salicylate in rheumatiod arthritis. Clin Pharmacol Ther 22: 410–420, 1977.PubMedGoogle Scholar
  198. 194.
    Wolfe F, Hawley DJ: Remission in rheumatoid arthritis. J Rheumatol 12: 245–252, 1985.PubMedGoogle Scholar
  199. 195.
    Halla JT, Hardin JG: Salicylate ototoxicity in rheumatoid arthritis: A controlled study. Ann Rheum Dis 47: 134–137, 1988.PubMedGoogle Scholar
  200. 196.
    Day RO, Furst DE, Dromogoole SH, et al.: Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clin Pharmacol Ther 31: 733–740, 1982.PubMedGoogle Scholar
  201. 197.
    Wilson JT, Brown RD, Kearns GL, et al.: Single-dose, placebo-controlled comparative study of ibuprofen and acetaminophen antipyresis in children. J Pediatr 119: 803–811, 1991.PubMedGoogle Scholar
  202. 198.
    Jacobs JC: New Frontiers in Pediatric Rheumatology. World Health Communications, New York, 1986.Google Scholar
  203. 199.
    Brewer EJ, Giannini EH, Barkley E: Gold therapy in the management of juvenile rheumatoid arthritis. Arthritis Rheum 23: 404–411, 1980.PubMedGoogle Scholar
  204. 200.
    Roine R, Gentry T, Hernandez-Munoz R, et al.: Aspirin increases blood alcohol concentrations in humans after ingestion of ethanol. JAMA 264: 2406–2408, 1990.PubMedGoogle Scholar
  205. 201.
    Jusko WJ, Rose JQ: Monitoring prednisone and prednisolone, In Tognoni G, Latini R, Jusko WJ (eds.) Frontiers in Therapeutic Drug Monitoring. Raven Press, New York, 1980, pp. 153–161.Google Scholar
  206. 202.
    Nelson AM, Conn DL: Glucocorticoids in rheumatic disease. Mayo Clin Proc 55: 758–769, 1980.PubMedGoogle Scholar
  207. 203.
    Byron MA, Jackson J, Ansell BM: Effect of different corticosteroid regimens on hypothalamic-pituitary-adrenal axis and growth in juvenile chronic arthritis. JR Soc Med 76: 452–457, 1983.Google Scholar
  208. 204.
    Schurmeyer TH, Tsokos GC, Avgerinos PC, et al.: Pituitary-adrenal responsiveness to corticotropin-releasing hormone in patients receiving chronic, alternate day glucocorticoid therapy. J Clin Endocrinol Metab 61: 22, 1985.PubMedGoogle Scholar
  209. 205.
    Moell C, Aronson AS, Selvik G: Growth in rabbits during alternate-day cortisone injections: near normal growth on days without cortisone. Acta Paediatr Scand 77: 693–698, 1988.PubMedGoogle Scholar
  210. 206.
    Fauci AS: Corticosteroids in autoimmune disease. Hosp Pract pp. 99–114; October 1983.Google Scholar
  211. 207.
    Kaplan PW, Rocha W, Sanders DB, et al.: Acute steroid-induced tetraplegia following status asthmaticus. Pediatrics 78: 121–123, 1986.PubMedGoogle Scholar
  212. 208.
    Nashel DJ: Is atherosclerosis a complication of long-term corticosteroid treatment? Am J Med 80: 925–929, 1986.PubMedGoogle Scholar
  213. 209.
    Baer PA, Shore A, Ikeman RL: Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis. Arthritis Rheum 30: 345–347, 1987.PubMedGoogle Scholar
  214. 210.
    Klinenberg JR, Miller R: Effect of corticosteroids on blood salicylate concentrations. JAMA 194: 601–604, 1965.PubMedGoogle Scholar
  215. 211.
    Tanchyk AP. Prevention of tooth erosion from salicylate therapy in juvenile rheumatoid arthritis. Gen Dent 34: 479–480, 1986.PubMedGoogle Scholar
  216. 212.
    Forsyth BW, Horwitz RI, Acampora D, et al.: New epidemologic evidence confirming that bias does not explain the aspirin/Reye’s Syndrome association. JAMA 261: 2517–2524, 1989.PubMedGoogle Scholar
  217. 213.
    Remington PL, Shabino CL, McGee H, et al.: Reye syndrome and juvenile rheumatoid arthritis in Michigan. Am J Dis Child 139: 870–872, 1985.PubMedGoogle Scholar
  218. 214.
    Rennebohm RM, Heubi JE, Daughtery CC, et al.: Reye syndrome in children receiving salicylate therapy for connective tissue disease. J Pediatr 107: 877–880, 1985.PubMedGoogle Scholar
  219. 215.
    Hollister JR: Aspirin in juvenile rheumatoid arthritis. Am J Dis Child 139: 866–867, 1985.PubMedGoogle Scholar
  220. 216.
    Kaneshiro MM, Mielke CH Jr, Kasper CK, et al.: Bleeding time after aspirin in disorders of intrinsic clothing. N Engl J Med 281: 1039–1042, 1969.PubMedGoogle Scholar
  221. 217.
    Quick AJ: Salicylates and bleeding: the aspirin tolerance test. Am J Med Sci 252: 265–269, 1966.PubMedGoogle Scholar
  222. 218.
    Rajah SM, Penny A, Kester R: Aspirin and bleeding time. Lancet 2: 1104, 1978.PubMedGoogle Scholar
  223. 219.
    Estes D, Kaplan K: Lack of platelet effect with aspirin analog salsalate. Arthritis Rheum 23: 1303–1307, 1980.PubMedGoogle Scholar
  224. 220.
    Goldsweig HG, Kapusta M, Schwartz J: Bleeding, salicylates and prolonged prothrombin time: three case reports and a review of the literature. J Rheum 3: 37–42, 1976.PubMedGoogle Scholar
  225. 221.
    Mills DG, Borda IT, Philp RB, et al.: Effects of in viro aspirin on blood platelets of gastrointestinal bleeders. Clin Pharmacol Ther 15: 187–192, 1974.PubMedGoogle Scholar
  226. 222.
    Rees WD, Turnberg LA: Reappraisal of the effects of aspirin on the stomach. Lancet 2: 410–413, 1980.PubMedGoogle Scholar
  227. 223.
    Manso C, Taranta A, Nydick I. Effects of aspirin administration on serum glutamic oxaloacetic and glutamic pyruvic transaminases in children. Proc Soc Exp Biol Med 93: 83–88, 1956.Google Scholar
  228. 224.
    Schaller JG: Chronic salicylate administration in juvenile rheumatoid arthritis: aspirin “hepatitis” and its clinical significance. Pediatrics 62: 916–925, 1978.PubMedGoogle Scholar
  229. 225.
    Iancu T, Elian E. Ultrastructural changes in aspirin hepatotoxicity. Am J Clin Pathol 66: 570–575, 1976.PubMedGoogle Scholar
  230. 226.
    Levinson JE, Brewer E Jr, Hanson V, et al.: Comparison of tolmetin sodium and aspirin in the treatment ofjuvenile rheumatoid arthritis. J Pediatr 91: 799–804, 1977.PubMedGoogle Scholar
  231. 227.
    Leonards JR, Levy G: Aspirin-induced occult gastrointestinal blood loss: Local versus systemic effects. J Pharm Sci 59: 1511–1513, 1970.PubMedGoogle Scholar
  232. 227a.
    Cryer B, Feldman M: Effects of non-steroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of non-steroidal anti-inflammatory drug-induced damage. Arch Intern Med 152: 1145–1155, 1992.PubMedGoogle Scholar
  233. 228.
    Hopkinson N, Doherty M: NSAID-associated gastropathy-a role for misoprostol? Br J Rheumatol 29: 133–136, 1990.PubMedGoogle Scholar
  234. 229.
    Gonwa TA, Hamilton RW, Buckalew VM Jr: Chronic renal failure and end-stage renal disease in northwest North Carolina. Arch Intern Med 141: 462–465, 1981PubMedGoogle Scholar
  235. 230.
    Dixon A, Martin BK, Smith MJ, et al. (eds.): Salicylates, An International Symposium. Churchill Livingstone, London, 1963.Google Scholar
  236. 231.
    Hoftiezer JW, Burks M, Silvoso GR, et al.: Comparison of the effects of regular and enteric-coated aspirin on the gastroduodenal mucosa of man. Lancet 2: 609–612, 1980.PubMedGoogle Scholar
  237. 232.
    Orozco-Alcala JJ, Baum J: Regular and enteric-coated aspirin: A re-evaluation. Arthritis Rheum 22: 1034–1037, 1979.PubMedGoogle Scholar
  238. 233.
    Baum J: Aspirin in the treatment ofjuvenile arthritis. Am J Med 74 (6A): 10–15, 1983.PubMedGoogle Scholar
  239. 234.
    Clark RL, Lasagno L: How reliable are enteric-coated aspirin preparations? Clin Pharmacol Ther 6: 568–574, 1965.PubMedGoogle Scholar
  240. 235.
    McCarty DJ, Csuka M-E: Aspirin in the treatment of chronic inflammatory arthritis. JAMA 257: 13–31, 1987.Google Scholar
  241. 236.
    Wiseman EH: Plasma salicylate concentrations following chronic administration of aspirin as conventional and sustained release tablets. Curr Ther Res 11: 681–688, 1969.PubMedGoogle Scholar
  242. 237.
    American Academy of Pediatrics: Committee on School Health: Administration of medication in school. Pediatrics 74: 433, 1984.Google Scholar
  243. 238.
    Wasner C, Britton MC, Kraines RG, et al.: Non-steroidal antiinflammatory agents in rheumatoid arthritis and ankylosing spondylitis. JAMA 246: 2168–2172, 1981.PubMedGoogle Scholar
  244. 238a.
    McConnell RJ: Abnormal thyroid function test results in patients taking salsa-late. JAMA 267: 1242–1243, 1992.PubMedGoogle Scholar
  245. 239.
    Guindo J, Rodriguez de la Sema A, Ramio J, et al.: Recurrent Pericarditis-Relief with colchicine. Cirulation 82:1117–1120, 1990 (See also: Correspondence pp. 1458–1459 and 1830–1831).Google Scholar
  246. 240.
    Goldenbery J, Pessoa AP, Roizenblatt S, et al.: Cardiac tamponade in juvenile chronic arthritis: report of two cases and review of publications. Ann Rheum Dis 49: 549–553, 1990.Google Scholar
  247. 241.
    Scharf J, Levy J, Benderly A, et al.: Pericardial tamponade in juvenile rheumatoid arthritis. Arthritis Rheum 19: 760–762, 1976.PubMedGoogle Scholar
  248. 242.
    Oakes DD, Light JA, Weidig JC, et al.: Methyl prednisone in uremic pericarditis. Lancet 1: 1312–1313, 1977.Google Scholar
  249. 243.
    Buselmeier TJ, Davin TD, Simmons RL, et al.: Treatment of intractable uremic pericardial effusion: avoidance of pericardiectomy with local steroid instillation. JAMA 240: 1358–1359, 1978.PubMedGoogle Scholar
  250. 244.
    Feigenbaum SL, Masi AT, Kaplan SB: Prognosis in rheumatoid arthritis. A longitudinal study of newly diagnosed younger adult patients. Am J Med 66: 377–384, 1979.PubMedGoogle Scholar
  251. 245.
    Maldonado-Cocco JA, Garica-Morteo O, Spindler AJ, et al.: Carpal ankylosis in juvenile rheumatoid arthritis. Arthritis Rheum 23: 1251–1255, 1980.PubMedGoogle Scholar
  252. 246.
    Scott PJ, Ansell BM, Huskisson EG: Measurement of pain in juvenile chronic polyarthritis. Ann Rheum Dis 36: 186–187, 1977.PubMedGoogle Scholar
  253. 247.
    Hochberg MC, Chang RW, Dwosh I, et al.: The American College of Rheumatology revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35: 498–502, 1992.PubMedGoogle Scholar
  254. 248.
    Wolfe F, Hawley DJ: Remission in rhuematoid arthritis. J Rheumatol 12: 245–252, 1985.PubMedGoogle Scholar
  255. 249.
    Nepom BS, Nepom GT, Mickleson E, et al.: Specific HLA-DR4 associated histo-compatibility molecules characterize patients with seropositive juvenile rheumatoid arthritis. J Clin Invest 76: 287–291, 1984.Google Scholar
  256. 250.
    Walker SM, McCurdy DK, Shaham B, et al.: High prevalence of IgA rheumatoid factor in severe polyarticular-onsetjuvenile rheumatoid arthritis, but not in systemic-onset or pauciarticular-onset disease. Arthritis Rheum 33: 199–204, 1990.PubMedGoogle Scholar
  257. 251.
    Harris ED Jr.: Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 322: 1277–1289, 1990.PubMedGoogle Scholar
  258. 252.
    Sherry DD, Bohnsack J, Salmonson K, et al.: Painless juvenile rheumatoid arthritis. J Pediatr 116: 921–923, 1990.PubMedGoogle Scholar
  259. 253.
    Bywaters EGL, Glynn LE, Zeldis A: Subcutaneous nodules of Still’s disease. Ann Rheum Dis 17: 278–285, 1958.PubMedGoogle Scholar
  260. 254.
    Hough, AJ Jr, Sokoloff L: The pathology of rheumatoid arthritis and related disorders. In McCarthy DJ (ed.) Arthritis and Allied Conditions, 11th ed. Lea and Febiger, Philadelphia, 1989, pp. 674–697.Google Scholar
  261. 255.
    Gardiner DL: Structure and function of connective tissue and joints. In Scott JT (ed.) Copeman’s Textbook of the Rheumatic Diseases, 5th ed. Churchill Livingstone, Edinburgh, 1978, pp. 78–124.Google Scholar
  262. 256.
    Scientific basis for the study of the rheumatic diseases. In McCarty DJ (ed.) Arthritis and Allied Conditions, 11th ed., Section II. Lea and Febiger, Philadelphia, 1989, pp. 189–504.Google Scholar
  263. 257.
    Stabrun AE, Larheim TA, Hoyeraal HM, Rosier M: Reduced mandibular dimensions and asymmetry in juvenile rheumatoid arthritis. Arthritis Rheum 31: 602–611, 1988.PubMedGoogle Scholar
  264. 258.
    Engel MB, Richmond J, Brodie AG: Mandibular growth disturbance in rheumatoid arthritis in childhood. Am J Dis Child 78: 728–743, 1949.PubMedGoogle Scholar
  265. 259.
    Myall RWT, West RA, Horwitz H, Schaller JG: Jaw deformity caused by juvenile rheumatoid arthritis and its correction. Arthritis Rheum 31: 1305–1310, 1988.PubMedGoogle Scholar
  266. 260.
    Espada G, Babini JC, Maldonado-Cocco JA, Garcia-Morteo O: Radiologic review: the cervical spine in juvenile rheumatoid arthritis. Semin Arthritis Rhuem 17: 185–195, 1988.Google Scholar
  267. 261.
    Fried JA, Athreya B, Gregg JR, et al.: The cervical spine in juvenile rheumatoid arthritis. Clin Orthop 179: 102–106, 1983.PubMedGoogle Scholar
  268. 262.
    Espada G, Babini JC, Maldonado-Cocco JA, Garcia-Morteo O: Radiologic review: The cervical spine in Juvenile rheumatoid arthritis. Semin Arthritis Rheum 17: 185–195, 1988.PubMedGoogle Scholar
  269. 263.
    Arroyo IL, Barron KS, Brewer EJ Jr.: Spinal cord compression by epidural lipomatosis in juvenile rheumatoid arthritis. Arthritis Rheum 31: 447–451, 1988.PubMedGoogle Scholar
  270. 264.
    D’Arch EJ, Fell RH: Anesthesia in juvenile chronic polyarthritis. In Arden GP, Ansell BM (eds.) Surgical Management of Juvenile Chronic Polyarthritis. Academic Press. London, 1978, pp. 63–74.Google Scholar
  271. 265.
    Scott RD, Sarokhan AJ, Dalziel R: Total hip and total knee arthroplasty in juvenile rheumatoid arthritis. Clin Orthop 182: 90–97, 1984.PubMedGoogle Scholar
  272. 266.
    Goldberg J, Kovarsky J: Beclomethasone dipropionate inhalation treatment for chronic hoarseness in rheumatic disease. Arthritis Rheum 26: 1412, 1983.PubMedGoogle Scholar
  273. 267.
    Pearson ME, Kosco M, Huffer W, et al.: Rheumatoid nodules of the spine: case report and review of the literature. Arthritis Rheum 30: 709–713, 1987.PubMedGoogle Scholar
  274. 268.
    Arden GP, Ansell BM (eds.). Surgical Management ofJuvenile Chronic Polyarthritis. Academic Press, London, 1978.Google Scholar
  275. 269.
    Ansell BM: Juvenile arthritis. Clin Rheum Dis 10: 657–672, 1984.PubMedGoogle Scholar
  276. 270.
    Vostrejs M, Hollister R: Muscle atrophy and leg length discrepancies in pauciarticular juvenile rheumatoid arthritis. Am J Dis Child 142: 343–345, 1988.PubMedGoogle Scholar
  277. 271.
    Stiehm ER: Nonsteroidal anti-inflammatory drugs in pediatric patients. Am J Dis Child 142: 1281–1282, 1988.PubMedGoogle Scholar
  278. 272.
    Rosenberg AM: Advanced drug therapy for juvenile rheumatoid arthritis. J Pediatr 114: 171–178, 1989.PubMedGoogle Scholar
  279. 273.
    Huskisson EC: Routine drug treatment of rheumatoid arthritis and other rheumatic diseases. Clin Rheum Dis 5: 697–706, 1979.Google Scholar
  280. 274.
    Herman JH, Appel AM, Hess EV: Modulation of cartilage destruction by select nonsteroidal antiinflammatory drugs. In vitro effect on the synthesis and activity of catabolism-inducing cytokines produced by osteoarthritic and rheumatoid synovial tissue. Arthritis Rheum 30:257–265, 1987.Google Scholar
  281. 275.
    Jacobs JC, Berdon WE, Johnston AD: HLA-B27 assoicated spondyloarthritis in childhood: Clinical, pathologic and radiographic observations in 58 patients. J Pediatr 100: 521–528, 1982.PubMedGoogle Scholar
  282. 276.
    Hart FD: Ankylosing spondylitis and related disorders. In Hart FD (ed.) Drug Treatment of the Rheumatic Diseases. Williams and Wilkins, Sydney, 1989, pp. 156–161.Google Scholar
  283. 277.
    Luggen ME, Gartside PS, Hess EV: Nonsteroidal antiinflammatory drugs in rheumatoid arthritis: duration of use as a measure of relative value. J Rheumatol 16: 1565–1569, 1989.PubMedGoogle Scholar
  284. 278.
    Pippenger CE: Therapeutic drug monitoring: An overview. Therap Drug Monit 1: 3–9, 1979.Google Scholar
  285. 279.
    Lovell DJ, Giannini EH, Brewer EJ Jr: Time course of response to non-steroidal antiinflammatory drugs in juvenile rheumatoid arthritis. Arthritis Rheum 27: 1433–1437, 1984.PubMedGoogle Scholar
  286. 280.
    Ehrlich GE: Tolmetin sodium: meeting the clinical challenge. Clin Rheum Dis 5: 481–497, 1979.Google Scholar
  287. 281.
    Makela AL: Naproxen in the treatment of juvenile rheumatoid arthritis. Scand J Rheumatol 6: 193–205, 1977.PubMedGoogle Scholar
  288. 282.
    Ansell BM, Hanna B, Moran H, et al.: Naproxen in juvenile chronic polyarthritis. Eur J Rheum Inflam 2: 79–83, 1979.Google Scholar
  289. 283.
    Nicholls A, Hazleman B, Todd RM, et al.: Long-term evaluation of naproxen suspension in juvenile chronic arthritis. Curr Med Res Opin 8: 204–207, 1982.PubMedGoogle Scholar
  290. 284.
    Williams PL, Ansell BM, Bell A, et al.: Multicentre study of piroxicam versus naproxen in juvenile chronic arthritis, with special reference to problem areas in clinical trials of nonsteroidal anti-inflammatory drugs in childhood. Br J Rheumatol 25: 67–71, 1986.PubMedGoogle Scholar
  291. 285.
    Leak AM, Richter MR, Clemens LE, et al.: A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. Clin Exp Rheumatol 6: 157–160, 1988.PubMedGoogle Scholar
  292. 286.
    Suarez SM, Cohen PR, DeLeo VA: Bullous photosensitivity to naproxen: “pseudoporhyria”. Arthritis Rheum 33: 903–908, 1990.PubMedGoogle Scholar
  293. 287.
    Levy ML, Barron KS, Eichenfield A, Honig PJ: Naproxen-induced pseudoporphyria: a distinctive photodermatitis. J Pediatr 117: 660–664, 1990.PubMedGoogle Scholar
  294. 287a.
    Goodwin SD, Glenny RW: Nonsteroidal anti-inflammatory drug-associated infiltrates with eosinophilia. Arch Intern Med 152: 1521–1524, 1992.PubMedGoogle Scholar
  295. 288.
    Giannini EH, Brewer EJ, Miller ML, et al.: Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. J Pediatr 117: 645–652, 1990.PubMedGoogle Scholar
  296. 289.
    Rhymer AR, Gengos DC: Indomethacin. Clin Rheum Dis 5: 541–552, 1979.Google Scholar
  297. 290.
    Jacobs JC: Sudden death in arthritic children receiving large doses of indomethacin. JAMA 199: 932–934, 1967.PubMedGoogle Scholar
  298. 291.
    Editorial. Analgesics, agranulocytosis, and aplastic anaemia: A major case-controlled study. Lancet 2: 899–900, 1986.Google Scholar
  299. 292.
    Brewer EJ, Giannini EH, Baum J, et al.: Aspirin and fenoprofen (NalfonR) in the treatment of juvenile rheumatoid arthritis: results of the double blind-trial. A Segment II Study. J Rheumatol 9: 123–128, 1982.PubMedGoogle Scholar
  300. 293.
    Bass J, Athreya B, Brandstrup N, et al.: Flurbiprofen in the treatment of juvenile rheumatoid arthritis. J Rheumatol 13: 1081–1083, 1986.PubMedGoogle Scholar
  301. 294.
    Brewer EJ, Giannini EH, Baum J, et al.: Ketoprofen (OrudisR) in the treatment of juvenile rheumatoid arthritis. A Segment I Study. J Rheumatol 9: 144–148, 1982.PubMedGoogle Scholar
  302. 295.
    Brewer EJ, Giannini EH, Baum J, et al.: Proquazone (BiarsanR) in the treatment of juvenile rheumatoid arthritis: A segment I study. J Rheumatol 5: 135–139, 1982.Google Scholar
  303. 296.
    Brewer EJ, Giannini EH, Baum J, et al.: Sodium meclofenamate (MeclomenR) in the treatment of juvenile rheumatoid arthritis. A segment I Study. J Rheumatol 9: 129–134, 1982.PubMedGoogle Scholar
  304. 297.
    Bass JC, Giannini EH, Brewer EJ, et al.: Pirprofen (Rengasi1R) in the treatment of juvenile rheumatoid arthritis. A segment I study. J Rheumatol 9: 140–143, 1982.PubMedGoogle Scholar
  305. 298.
    Bhettay E: Double-blind study of sulindac and aspirin in juvenile chronic arthritis. SAMJ 70: 724–726, 1986.PubMedGoogle Scholar
  306. 299.
    Haapasaari J, Wuolijoki E, Ylijoki H: Treatment of juvenile rheumatoid arthritis with diclofenac sodium. Scand J Rheumatol 12: 325–330, 1983.PubMedGoogle Scholar
  307. 300.
    Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J: Diclofenac-associated hepatotoxicity. JAMA 264:2660–2662 (see also editiorial pp. 2677–2678).Google Scholar
  308. 301.
    Paulus HE: FDA Arthritis Advisory Committee Meeting: risks of agranulocytosis/aplastic anemia, flank pain, and adverse gastrointestinal effects with use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 30: 593–595, 1987.Google Scholar
  309. 302.
    Cush JJ, Jasin HE, Johnson R, Lipsky PE: Relationship between clinical efficacy and laboratory correlates of inflammatory and immunologic activity in rheumatoid arthritis patients treated with nonsteroidal antiinflammatory drugs. Arthritis Rheum 33: 623–633, 1990.PubMedGoogle Scholar
  310. 303.
    Caille G, du Souich R, Gervais P, et al.: Effects of concurrent sucralfate administration on pharmacokinetics of naproxen. Am J Med 83 (Suppl 38) 67–73, 1987.PubMedGoogle Scholar
  311. 304.
    Howes CA, Pullar T, Sourindhrin I, et al.: Reduced steady-state plasma concentrations of chlorpromazine and indomethacin in patients receiving cimetidine. Eur J Clin Pharmacol 24: 99–102, 1983.PubMedGoogle Scholar
  312. 305.
    Graham DY: Prevention of gastroduodenal injury induced by chronic nonsteroidal antiinflammatory drug therapy. Gastroenterology 96: 675–681, 1989.PubMedGoogle Scholar
  313. 306.
    Roth S, Agrawal N, Mahowald M, et al.: Misoprostol heals gastroduodenal injury in patients with rheumatoid arthitis receiving aspirin. Arch intern Med 149: 775–779, 1989.PubMedGoogle Scholar
  314. 307.
    Furst DE, Sarkissian E, Blocka K, et al.: Serum concentrations of salicylate and naproxen during concurrent therapy in patients with rheumatoid arthritis. Arthritis Rheum 30: 1157–1161, 1987.PubMedGoogle Scholar
  315. O’Brien WM, Bagby GF: Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 12:13–20, 347–353, 562–567, 785–789, 1985.Google Scholar
  316. 307b.
    b.Hyson CP, Kazakoff MA: A servere multisystem reaction to sulindac. Arch Intern Med 151: 387–388, 1991.PubMedGoogle Scholar
  317. 308.
    Barrier CH, Hirschowitz BI: Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 32: 926–932, 1989.PubMedGoogle Scholar
  318. 309.
    Langman MJS: Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. Gastroenterology 96: 640–646, 1989.PubMedGoogle Scholar
  319. 310.
    Fries JF, Miller SR, Spitz PW, et al.: Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 96: 647–655, 1989.PubMedGoogle Scholar
  320. 310a.
    Gabriel SE, Bombardier C: NSAID induced ulcers. An emerging epidemic? J Rheumatol 17: 1–4, 1990.PubMedGoogle Scholar
  321. 310b.
    b.Gibson GR, Whitacre EB, Ricotti CA: Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature. Arch Intern Med 152: 625–632, 1992.PubMedGoogle Scholar
  322. 311.
    Hoppmann RA, Peden JG, Ober SK: Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 151: 1309–1013, 1991.PubMedGoogle Scholar
  323. 312.
    Lindsley CB, Warady BA: Nonsteroidal antiinflammatory drugs: renal toxicity: review of pediatric issues. Clin Pediatr 29: 10–113, 1990.Google Scholar
  324. 313.
    Robinson J, Malleson P, Lirenman D, Carter J: Nephrotic syndrome associated with nonsteroidal anti-inflammatory drug use in two children. Pediatrics 85: 844–847, 1990.PubMedGoogle Scholar
  325. 314.
    Tietjan DP: Recurrence and specificity of nephrotic syndrome due to tolmetin. Am J Med 87: 354–355, 1989.Google Scholar
  326. 315.
    Allen RC, Petty RE, Lirenman DS, et al.: Renal papillary necrosis in children with chronic arthritis. Am J Dis Child 140:20–22, 1986 (see also editorial pp. 16–17).Google Scholar
  327. 316.
    Laxer RM, Silverman ED, Balfe J-W, et al.: Naproxen-associated renal failure in a child with arthritis and inflammatory bowel disease. Pediatrics 80: 904–908, 1987.PubMedGoogle Scholar
  328. 317.
    Dunn MJ, Patrono C (eds.): Renal effects of nonsteroidal anti-inflammatory drugs. AJM 81(2B):1–132, 1986.Google Scholar
  329. 318.
    Warren GV, Korbet SM, Schwartz MM, Lewis EJ: Minimal change glomerulopathy associated with nonsteroidal antiinflammatory Drugs. Am J Kidney Dis 13: 127–130, 1989.PubMedGoogle Scholar
  330. 319.
    Schwarz A, Krause PH, Keller F, et al.: Granulomatous interstitial nephritis after nonsteroidal anti-inflammatory Drugs. Am J Nephrol 8: 410–416, 1988.PubMedGoogle Scholar
  331. 320.
    Stillman MT, Schlesinger PA: Nonsteroidal anti-inflammatory drug nephrotoxicity. Should we be concerned? Arch Intern Med 150: 268–270, 1990.PubMedGoogle Scholar
  332. 321.
    Ten RM, Torres VE, Milliner DS, et al.: Acute interstitial nephritis: Immunologic and clinical aspects. Mayo Clin Proc 63: 921–930, 1988.PubMedGoogle Scholar
  333. 322.
    Garella S, Matarese RA: Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine 63: 165–181, 1984.PubMedGoogle Scholar
  334. 323.
    Bender WL, WHelton A, Beschorner WE, et al.: Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs. Immunologic characterization of the inflammatory infiltrate. Am J Med 76: 1006–1012, 1984.PubMedGoogle Scholar
  335. 324.
    Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Eng J Med 310: 563–572, 1984.Google Scholar
  336. 324a.
    Cronberg S, Wallmark E, Soderberg I: Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 33: 155–159, 1984.PubMedGoogle Scholar
  337. 324b.
    b.Connelly CS, Panush RS: Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery? Arch Intern Med 151: 1963–1966, 1991.PubMedGoogle Scholar
  338. 325.
    Szer IS, Goldenstein-Schainberg C, Kurtin PS: Paucity of renal complications associated with nonsteroidal antiinflammatory drugs in children with chronic arthritis. J Pediatr 119: 815–817, 1991.PubMedGoogle Scholar
  339. 326.
    lannuzzi L, Dawson N, Zein N, Kushner I: Does drug therapy slow radiologic deterioration in rheumatoid arthritis? N Eng J Med 309: 1023–1028, 1983.Google Scholar
  340. 327.
    Scott DL, Symmons DPM, Coulton BL, Popert AJ: Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1: 1108–1111, 1987.PubMedGoogle Scholar
  341. 328.
    Pincus T (ed.) Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 41:1037–1041, 1988.Google Scholar
  342. 329.
    Dawes PT, Powler S, Clarke J, et al.: Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol 25: 44–49, 1986.PubMedGoogle Scholar
  343. 330.
    Grondin C, Malleson P, Petty RE: Slow-acting antirheumatic drugs in chronic arthritis of childhood. Semin Arthritis Rheum 18: 38–47, 1988.PubMedGoogle Scholar
  344. 331.
    Giannini EH, Brewer EJ, Kuzmina N, et al.: Characteristics of responders and nonresponders to slow-acting antirheumatic drugs in juvenile rheumatoid arthritis. Arthritis Rheum 31: 15–20, 1988.PubMedGoogle Scholar
  345. 332.
    Manners PJ, Ansell BM: Slow-acting antirheumatic drug use in systemic onset juvenile chronic arthritis. Pediatrics 77: 99–103, 1986.PubMedGoogle Scholar
  346. 333.
    Rosenberg AM: Advanced drug therapy for juvenile rheumatoid arthritis. J Pediatr 114: 171–178, 1989.PubMedGoogle Scholar
  347. 334.
    van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al.: Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1: 1036–1038, 1989.PubMedGoogle Scholar
  348. 335.
    Williams HJ, Ward JR, Dahl SL, et al.: A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 31: 702–713, 1988.PubMedGoogle Scholar
  349. 336.
    Ozdogan H, Turunc M, Deringol B, et al.: Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial. J Rheumatol 13: 124–125, 1986.PubMedGoogle Scholar
  350. 337.
    Jacobs JC: Sulphasalazine in the treatment of childhood arthritis: a preliminary report. Arthritis Rheum 33: S145, 1990.Google Scholar
  351. 338.
    Pinals RS: Sulfasalazine in the rheumatic disease. Semin Arthritis Rheum 17: 246–259, 1988.PubMedGoogle Scholar
  352. 339.
    Farr M, Kitas G, Waterhouse L, et al.: Sulfasalazine in psoriatic arthritis-A double blind placebo-controlled study. Br J Rheumatol 29: 46–49, 1990.PubMedGoogle Scholar
  353. 340.
    Job-Deslandre C, Menkes C-J. Sulphasalazine in the treatment of juvenile spondylarthropathy. Arthritis Rheum 34: S153, 1991.Google Scholar
  354. 341.
    Ansell BM, Hall MA, Woo LP, et al.: A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 9: 201–203, 1991.PubMedGoogle Scholar
  355. 342.
    Ansell BM: Juvenile chronic arthritis and juvenile spondyloarthropathy. Current Opin Rheumatol 3: 838–843, 1991.Google Scholar
  356. 343.
    Hertzberger-Ten Cate R, Cats A: Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheumatol 9: 85–88, 1991.PubMedGoogle Scholar
  357. 344.
    Sherry DD, Wallace CA. Sulfasalazine toxicity in children with systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 34: S153, 1991.Google Scholar
  358. 345.
    Felson DT, Andserson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33: 1449–1461, 1990.PubMedGoogle Scholar
  359. 346.
    Taffet SL, Das KM: Sulfasalazine: Adverse effects and desensitization. Dig Dis Sci 28: 833–842, 1983.PubMedGoogle Scholar
  360. 347.
    Amos RS, Pullar T, Bax DE, et al.: Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J 293: 420–423, 1986.Google Scholar
  361. 348.
    Marabani M, Madhok R, Capell HA, Hunter JA: Leuocopenia during sulphasalazine treatment for rheumatoid arthritis. Ann Rheum Dis 48: 505–507, 1989.PubMedGoogle Scholar
  362. 349.
    Farr M, Tunn EJ, Symmons DPM, et al.: Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy. Br J Rheumatol 28: 134–138, 1989.PubMedGoogle Scholar
  363. 350.
    Valcke Y, Pauwels R, van der Straeten M: Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine. Chest 92: 572–573, 1987.PubMedGoogle Scholar
  364. 351.
    Deboever G, Devogelaere R, Holvoet G: Sulphasalazine-induced lupus-like syndrome with cardiac tamponada in a patient with ulcerative colitis. Am J Gastroenterol 84: 85–86, January 1989.PubMedGoogle Scholar
  365. 352.
    Epstein WV: Parental gold therapy for rheumatoid arthritis: A treatment whose time has gone. J Rheumatol 16: 1291–1294, 1989.PubMedGoogle Scholar
  366. 353.
    Jessop, JD: Gold in the treatment of rheumatoid arthritis-why, when, how? J Rheum 6 (Suppl. 5): 12–17, 1979.Google Scholar
  367. 354.
    Empire Rheumatism Council: Gold therapy in rheumatoid arthritis. Final report of a multicenter controlled trial. Ann Rheum Dis 20: 315–354, 1961.Google Scholar
  368. 355.
    Epstein WV, Henke CJ, Yelin EH, Katz PP: Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis. Ann Intern Med 114: 437–444, 1991.PubMedGoogle Scholar
  369. 356.
    Levinson JE, Balz GP, Bondi S: Gold therapy. Arthritis Rheum 20: 531–535, 1977.Google Scholar
  370. 357.
    Hall MA, Ansell BM, Spencer PE: A comparative study of gold and penicillamine in juvenile chronic arthritis. Presented at the 15th International Congress of Rheumatology, Paris, 1981. Rev Rhum 48(Suppl):, abstract 1290, 1981.Google Scholar
  371. 358.
    Davis P: Undersirable effects of gold salts. J Rheum 6 (Suppl. 5): 18–24, 1979.Google Scholar
  372. 358a.
    Hansen RM, Varma RR, Hanson, GA: Gold induced hepatitis and pure red cell aplasia. Complete recovery after corticosteroid and N-Acetylcysteinc therapy. J Rheumatol 18: 1251–1253, 1991.PubMedGoogle Scholar
  373. 359.
    Wooley PH, Griffin J, Panayi GS, et al.: HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl Med 303: 300–302, 1980.Google Scholar
  374. 360.
    Takehara M, Beardmore T: Self administration of parenteral gold and methotrexate in rheumatoid arthritis. Arthritis Rheum 33: S16, 1990.Google Scholar
  375. 361.
    Gottlieb NL: Metabolism and distribution of gold compounds. J Rheum 6 (Suppl. 5): 2–6, 1979.Google Scholar
  376. 362.
    Gottlieb NL: Gold excretion and retention during auranofin treatment: A preliminary report. J Rheum 6 (Suppl. 5): 61–67, 1979.Google Scholar
  377. 363.
    Kvien TK, Hoyeraal HM, Sandstad B: Gold sodium thiomalate and Dpenicillamine. A controlled, comparative study in patients with pauciarticular and polyarticular juvenile rheumatoid arthritis. Scand J Rheumatol 14: 346–354, 1985.PubMedGoogle Scholar
  378. 364.
    Giannini EH, Brewer EJ Jr, Kuzmina N, et al.: Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. Arthritis Rheum 33:466–476, 1990 (see also correspondence 34: 934–935, 1991 ).Google Scholar
  379. 365.
    Katz WA, Blodgett RC Jr., Pietrusko RG: Proteinuria in gold-treated rheumatoid arthritis. Ann Intern Med 101: 176–179, 1984.PubMedGoogle Scholar
  380. 366.
    Marcolongo R, Mathieu A, Pala R, et al.: The efficacy and safety of auranofin in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 31: 979–983, 1988.PubMedGoogle Scholar
  381. 367.
    Giannini EH, Brewer EJ, Person DA: Blood gold concentrations in children with juvenile rheumatoid arthritis undergoing long-term oral gold therapy. Ann Rheum Dis 43: 228–231, 1984.PubMedGoogle Scholar
  382. 368.
    Giannini EH, Barron KS, Spencer CH, et al.: Auranofin therapy in juvenile rheumatoid arthritis: results of the five-year open-label extension trial, J Rheumatol 18: 1240–1242, 1991.PubMedGoogle Scholar
  383. 369.
    Bombardier C, Ware J, Russell IJ, et al.: Auranofin therapy and quality of life in patients with rheumatoid arthritis. Am J Med 81: 565–578, 1986.PubMedGoogle Scholar
  384. 370.
    Jaffe IA: Penicillamine treatment of rheumatoid arthritis-rationale, pattern of clinical response, and clinical pharmacology and toxicology. In Munthe E (ed.) Penicillamine Research Rheumatoid Disease (Penicillamine Symposium). Fabritius, Oslo, Norway, 1976. pp. 11–24.Google Scholar
  385. 371.
    Multz CV: Cholestatic hepatitis caused by penicillamine. JAMA 246: 674–675, 1981.PubMedGoogle Scholar
  386. 372.
    Hamilton EDB, Dixon A St J, Davis J, et al.: Multicentre trial with synthetic D-penicillamine in rheumatoid arthritis. JAMA 246: 215–218, 1981.Google Scholar
  387. 373.
    Hill HFH: Treatment of rheumatoid arthritis with penicillamine. Semin Arthritis Rheum 6: 361–388, 1977.PubMedGoogle Scholar
  388. 374.
    Kean WF, Dwosh IL, Anastassiades TP, et al.: The toxicity pattern of penicillamine therapy. A guide to its use in rheumatoid arthritis. Arthritis Rheum 23: 158–164, 1980.PubMedGoogle Scholar
  389. 375.
    Schairer H, Stoeber E: Long-term follow-up of 235 cases of juvenile rheumatoid arthritis treated with D-penicillamine. In Munthe E (ed.) Penicillamine Research in Rheumatoid Disease (Penicillamine Symposium). Fabritius, Oslo, Norway, 1977, pp. 279–281.Google Scholar
  390. 376.
    Ansell BW, Hall MA: Penicillamine in chronic arthritis in childhood. J. Rheum 8 (Suppl. 7): 112–115, 1981.Google Scholar
  391. 377.
    Brewer EJ, Giannini EH, Kuzmina N, Alekseev L: Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. New Eng J Med 314:1269–1276, 1986 (see also editorial pp. 1312–1314).Google Scholar
  392. 378.
    Prieur AM, Piussan C, P Manigne, et al.: Evaluation of D-penicillamine in juvenile chronic arthritis. A double-blind mutlicentre study. Arthritis Rheum 28: 376–382, 1985.PubMedGoogle Scholar
  393. 379.
    Felson DT, Anderson JJ, Meenan RF: Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum 33: 140–149, 1990.PubMedGoogle Scholar
  394. 380.
    Paulus HE, Egger MJ, Ward JR, et al.: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 33: 477–484, 1990.PubMedGoogle Scholar
  395. 381.
    Hall CL, Jawad S, Harrison PR, et al.: Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J 296: 1083–1086, 1988.Google Scholar
  396. 382.
    Halla JT, Fallahi S, Koopman WJ: Penicillamine-induced myositis. Observations and unique features in two patients and review of the literature. Am J Med 77: 719–722, 1984.PubMedGoogle Scholar
  397. 383.
    Jaffe IA: Adverse effects profile of sulfhydryl compounds in man. Am J Med 80: 471–476, 1986.PubMedGoogle Scholar
  398. 384.
    Benson EA, Healey LA, Barron EJ: Insulin antibodies in patients receiving penicillamine. Am J Med 78: 857–860, 1985.PubMedGoogle Scholar
  399. 385.
    van Kerckhove C, Giannini EH, Lovell DJ: Temporal patterns of response to D-penicillamine, hydroxychloroquine and placebo in juvenile pheumatoid arthritis. Arthritis Rheum 31: 1252–1258, 1988.PubMedGoogle Scholar
  400. 386.
    Huskisson EG: Drugs which apparently affect the rheumatoid disease process. In Hart FD (ed.) Drug Treatment of the Rheumatic Disease. Williams and Wilkins, Sydney, 1987, pp. 65–87.Google Scholar
  401. 387.
    Zvaifler NJ (ed): Update in rheumatology: focus on hydroxychloroquine. Am J Med 85:1–71, 1988.Google Scholar
  402. 388.
    Laaksonen A, Koskiande V, Juka K: Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentration of chloroquine and hydroxychloroquine. Scand J Rheum 3: 103–108, 1974.PubMedGoogle Scholar
  403. 389.
    Stillman S: Antimalarials. In Moore TD (ed.) Arthritis in Childhood. Report of the 80th Ross Conference on Pediatric Research. Xanadu, Bahamas, December 2–5, 1979. Ross Laboratories. Columbus, OH, 1981, pp. 125–127.Google Scholar
  404. 390.
    Kvien TK, Hoyeraal HM, Sandstad B: Slow acting antirheumatic drugs in patients with juvenile rheumatoid arthritis—evaluated in a randomized, parallel 50-week clinical trial. J Rheumatol 12: 533–539, 1985.PubMedGoogle Scholar
  405. 391.
    Maksymowych W, Russell AS: Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 16: 206–221, 1987.PubMedGoogle Scholar
  406. 392.
    Rynes, RI, Krohel G, Falbo A, et al.: Ophthalmologic safety of long-term hydroxychloroquine treatment. Arthritis Rheum 22: 832–836, 1979.PubMedGoogle Scholar
  407. 392a.
    Bernstein HN: Ocular Safety of hydroxychloroquine. Ann Ophthalmol 23: 292–296, 1991.PubMedGoogle Scholar
  408. 393.
    Beultler E: Glucose-6-phosphate dehydrogenase deficiency. N Eng J Med 324: 169–174, 1991.Google Scholar
  409. 394.
    Fries JF, Singh G, Lenert L, Furst DE: Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 33: 1611–1619, 1990.PubMedGoogle Scholar
  410. 395.
    Jaffe KM, Havens PL, et al.: Childhood chloroquine poisonings—Wisconsin and Washington. JAMA 260: 13–61, 1988.Google Scholar
  411. 396.
    Ratliff NB, Estes ML, Myles JL, et al.: Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Eng J Med 316: 191–193, 1987.Google Scholar
  412. 397.
    Estes ML, Ewing-Wilson D, Chou SM, et al.: Chloroquine neuromyotoxicity: clinical and pathologic perspective. Am J Med 82: 447–455, 1987.PubMedGoogle Scholar
  413. 398.
    Wallace CA, Bleyer WA, Sherry DD, et al.: Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 32: 677–681, 1989.PubMedGoogle Scholar
  414. 399.
    Shiroky JH, Watts CS, Neville C: Combination methotrexate and sulfasalazine in the management of rheumatoid arthritis: case observations. Arthritis Rheum 32: 1160–1164, 1989.PubMedGoogle Scholar
  415. 400.
    Klippel JH, Strober S, Wofsy D: New therapies for the rheumatic diseases. Bull Rheum Dis 38 (#4): 1–8, 1989.PubMedGoogle Scholar
  416. 401.
    Paulus HE: The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis. Arthritis Rheum 33: 113–120, 1990.PubMedGoogle Scholar
  417. 401a.
    Williams HJ, Ward JR, Reading JC, et al.: Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 35: 259–269, 1992.PubMedGoogle Scholar
  418. 402.
    Arthritis Foundation: Challenging the pyramid. A new look at therapeutic approaches for rheumatoid arthritis. J Rheumatol 17:Suppl 25, Nov. 1990. (See also Editorial, 17: 1115–1118, 1990.Google Scholar
  419. 402a.
    McCarty DJ: Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians J Rheum 17: 1115–1118, 1990.Google Scholar
  420. 403.
    Jacobs JC: Juvenile rheumatoid arthritis. In Downey JA, Low NL (eds.) The Child with Disabling Illness, 2nd ed. Raven Press, New York, 1982, pp. 3–27.Google Scholar
  421. 404.
    Joint Committee of the Medical Research Council and Nuffield Foundation: a comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 18:173, 1959.Google Scholar
  422. 405.
    Harris ED Jr, Emkey RD, Nichols JE, Newberg A: Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol 10: 713–721, 1983.PubMedGoogle Scholar
  423. 406.
    Jacobs JC: The arthritic child and the family: Staying in the mainstream. Arthritis Rheum 20: 595–597, 1977.Google Scholar
  424. 407.
    De Palma AF, McKeeve CD, Jubin DK: Process of repair of articular cartilage demonstrated by histology and autoradiography with tritiated thymidine. Clin Orthop 48: 229–242, 1966.Google Scholar
  425. 408.
    Palmoski M, Perricone E, Brandt KD: Development and reversal of a proteoglycan aggregation defect in normal canine knee cartilage after immobilization. Arthritis Rheum 22: 508–517, 1979.PubMedGoogle Scholar
  426. 409.
    Palmoski MJ, Colyer RA, Brandt TKD: Joint motion in the absence of normal loading does not maintain normal articular cartilage. Arthritis Rheum 23: 325–334, 1980.PubMedGoogle Scholar
  427. 410.
    Johnson RF: The effect of immobilization on ligaments and ligamentous healing. Contemp Orthop 2: 237–241, 1980.Google Scholar
  428. 411.
    Bernstein B, Forrester D, Singsen B, et al.: Hip joint restoration in juvenile rheumatoid arthritis. Arthritis Rheum 20: 1099–1104, 1977.PubMedGoogle Scholar
  429. 412.
    Elsasser U, Wilkins B, Hesp R: Bone rarefaction and crush fractures in juvenile chronic arthritis. Arch Dis Child 57: 377–380, 1982.PubMedGoogle Scholar
  430. 413.
    Jacobs JC, Dick HM, Downey JA, et al.: Weight bearing as a treatment for damaged hips in juvenile rheumatoid arthritis. N Engl J Med 305: 409, 1981.PubMedGoogle Scholar
  431. 414.
    McAllister WAC, Thompson RJ, Al-Habet SM, et al.: Rifampin reduces effectiveness and bioavailability of prednisolone. Br Med J 286: 923–925, 1983.Google Scholar
  432. 415.
    Nishioka T, Kurayama H, Yasuda T, et al.: Nasal administration of salmon calcitonin for prevention of glucocorticord-induced osteosporosis in children with nephrosis. J Pediatr 118: 703–707, 1991.PubMedGoogle Scholar
  433. 416.
    Loftus J, Allen R, Hesp R, et al.: Randomized, double-blind trial of Deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: A relatively bone-sparing effect of Deflazacort. Pediatrics 88: 428–436, 1991.PubMedGoogle Scholar
  434. 417.
    Liebing MR, Leib E, McLaughlin K, et al.: Pulse methylprednisolone in rheumatoid arthritis. Ann Intern Med 94: 21–26, 1981.Google Scholar
  435. 418.
    Miller JJ: Prolonged use of intravenous steroid pulses in the rheumatic diseases of children. Pediatrics 65: 980–994, 1980.Google Scholar
  436. 419.
    Barry M: The use of high-dose pulse methylprednisolone in rheumatoid arthritis. Unproved therapy. Arch Intern Med 145: 1483–1484, 1985.PubMedGoogle Scholar
  437. 420.
    Silverman ED, Laxer RM, Greenwald M, et al.: Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum 33: 1015–1022, 1990.PubMedGoogle Scholar
  438. 421.
    Groothoff JW, van Leeuwen EF: High dose intravenous gammaglobulin in chronic systemic juvenile arthritis. Br Med J 296: 1362–1363, 1988.Google Scholar
  439. 422.
    Becker H, Mitropoulou G, Helmke K: Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin. KIM Wochenschr 67: 286–290, 1980.Google Scholar
  440. 423.
    Combe B, Cosso B, Clot J, et al.: Human placenta-eluted gammaglobulins in immunomodulating treatment of rheumatoid arthritis. Am J Med 78: 920–928, 1985.PubMedGoogle Scholar
  441. 424.
    Landsbury J: Quantitation of the activity of rheumatoid arthritis. I. A method for recording its systemic manifestations. Am J Med Sci 231: 616–621, 1956.Google Scholar
  442. 425.
    Bunch TW, O’Duffy JD: Disease modifying drugs for progressive rheumatoid arthritis. Mayo Clin Proc 55: 161–179, 1980.PubMedGoogle Scholar
  443. 426.
    Wallace CA, Bleyer WA, Sherry DD, et al.: Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthirits Rheum 32: 677–681, 1989.Google Scholar
  444. 427.
    Rose CD, Singsen BH, Eichenfield AH, et al.: Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 117:653–659, 1990. (See also: Correspondence 119: 333–334, 1991.Google Scholar
  445. 428.
    Singh G, Fries JF, Williams CA, et al.: Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 18: 188–194, 1991.PubMedGoogle Scholar
  446. 429.
    Jeurissen ME, Boerbooms AM, van de Putte LB, et al.: Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized double-blind study. Ann Intern Med 114: 999–1004, 1991.PubMedGoogle Scholar
  447. 430.
    Kremer JM, Phelps CT: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 35: 138–45, 1992.PubMedGoogle Scholar
  448. 431.
    Williams HJ, Willkens RF, Samuelson CO, et al.: Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 28: 721–730, 1985.PubMedGoogle Scholar
  449. 432.
    Truckenbrodt H, Hafner R: Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum 29: 801–807, 1986.PubMedGoogle Scholar
  450. 433.
    Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. NEJM 326: 1043–1049, 1992.PubMedGoogle Scholar
  451. 434.
    Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM: Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 120: 468–73, 1992.PubMedGoogle Scholar
  452. 435.
    Giannini EH, Shaikov A, Maximov A, et al.: Meta-analysis of antirheumatic drug trials in juvenile rheumatoid arthritis. Arthritis Rheum 34: S152, 1991.Google Scholar
  453. 436.
    Wallace C, Sherry D, Salmonson K: Treatment of juvenile rheumatoid arthritis with higher dose methotrexate. Arthritis Rheum 33: S39, 1990.Google Scholar
  454. 437.
    Jundt JM, Browne BA, Mock D, et al.: Methotrexate pharmacokinetics in rheumatoid arthritis. Arthritis Rheum 33: 561, 1990.Google Scholar
  455. 438.
    Mandel MA: The synergistic effect of salicylates on methotrexate toxicity. Plast Recontruct Surg 57: 733–737, 1976.Google Scholar
  456. 439.
    Taylor JR, Halprin KM: Effect of sodium salicylate and indomethacin on methotrexate-serum albumin binding. Arch Dermatol 113: 588–591, 1977.PubMedGoogle Scholar
  457. 440.
    Dupuis LL, Koren G, Shore A, et al.: Methotrexate-Nonsteroidal antiinflamatory drug interaction in children with arthritis. J Rheumatol 17: 1469–1473, 1990.PubMedGoogle Scholar
  458. 440.
    Weinblatt ME, Weissman BN, Holdsworth DE, et al.: Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 35: 129–37, 1992.PubMedGoogle Scholar
  459. 441.
    Nordstrom DM, West SG, Andersen PA, Sharp JT: Pulse methotrexate therapy in rheumatoid arthritis. Ann Intern Med 107: 797–801, 1987.PubMedGoogle Scholar
  460. 441a.
    Rau R, Herborn G, Karger T, Werdier D: Retardation of radiologic progression in rheumatoid arthritis with methotrexate therapy. A controlled study. Arthritis Rheum 84: 1236–1244, 1991.Google Scholar
  461. 442.
    Kremer JM, Rynes RI, Bartholomew LE: Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Am J Med 82: 781–786, 1987.PubMedGoogle Scholar
  462. 443.
    Flowers MA, Heathcote J, Wanless IR, et al.: Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 112: 381–382, 1990.PubMedGoogle Scholar
  463. 444.
    Alarcon GS, Tracy IC, Blackburn WD Jr.: Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 32: 671–676, 1989.PubMedGoogle Scholar
  464. 445.
    Bjorkman DJ, Hammond EH, Lee RG, et al.: Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 31: 1465–1472, 1988.PubMedGoogle Scholar
  465. 446.
    Aponte J, Petrelli M: Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate. Arthritis Rheum 31: 1457–1464, 1988.PubMedGoogle Scholar
  466. 447.
    Kremer JM, Lee RG, Tolman KG: Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 32: 121–127, 1989.PubMedGoogle Scholar
  467. 448.
    Shergy WJ, Polisson RP, Caldwell DS, et al.: Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 85: 771–774, 1988.PubMedGoogle Scholar
  468. 449.
    Brick JE, Moreland LW, Al-Kawas F, et al.: Prospective anaylsis of liver biopsies before and after methotrexate therapy in rheumatoid patients. Semin Arthritis Rheum 19: 31–44, 1989.PubMedGoogle Scholar
  469. 449a.
    Keim D, Ragadalc C, Heidelberger K, Sullivan D: Hepatic fibrosis with the use of methothexate for juvenile arthritis. J Rheumatol 17: 846–848, 1990.PubMedGoogle Scholar
  470. 450.
    Phillips C, Cera P, Mangan T, Newman E: Severe liver disease (SLD) in rheumatoid arthritis (RA) patients on methotrexate (MTX). Arthritis Rheum 33:#5 (Suppl): R15, 1990.Google Scholar
  471. 451.
    Whiting-O’Keefe QE, Fye KH, Sack KD: Methotrexate and histologic hepatic abnormalities: A meta-analysis. Am J Med 90: 711–716, 1991.PubMedGoogle Scholar
  472. 452.
    Keim DR, Godoshian-Ragsdale C, Sullivan DB: Liver biopsy with the use of methotrexate for juvenile rheumatoid arthritis. J Pediatr 118: 654, 1991.PubMedGoogle Scholar
  473. 452a.
    Hall P ole la M, Ahern MJ, Jarvis LR, et al.: Two methods of assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis. Ann Rheum Dis 50: 471–476, 1991.Google Scholar
  474. 453.
    Carson CW, Cannon GW, Egger MJ, et al.: Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 16: 186–195, 1987.PubMedGoogle Scholar
  475. 454.
    Furst DE, Kremer JM: Methotrexate in rheumatoid arthritis. Arthritis Rheum 31: 305–314, 1988.PubMedGoogle Scholar
  476. 455.
    Wernick R, Smith DL: Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum 32: 770–775, 1989.PubMedGoogle Scholar
  477. 456.
    Shupack JL, Webster GF: Pancytopenia following low-dose oral methotrexate therapy for psoriasis. JAMA 259: 3594–3596, 1988.PubMedGoogle Scholar
  478. 457.
    Scalone J, Bowen JR: Methotrexate osteopathy: case report. Contemp Orthop 17: 46–49, 1988.Google Scholar
  479. 458.
    Lopez-Mendez A, Bridges SL Jr., Han K, et al.: Methotrexate increases risk of post-surgical complications in rheumatoid arthritis patients. Arthritis Rheum 33:#5 (Suppl) R131, 1990.Google Scholar
  480. 459.
    Tugwell P, Bombardier C, Buchanan WW, et al.: Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med 150: 59–62, 1990.PubMedGoogle Scholar
  481. 460.
    Weinblatt ME, Kaplan H, Germain BF, et al.: Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six week, double-blind trial. Arthritis Rheum 33: 330–338, 1990.PubMedGoogle Scholar
  482. 461.
    Shiroky J, Neville C, Esdaile J, Skelton J: High dose methotrexate with leucovorin rescue in the management of rheumatoid arthritis. Arthritis Rheum 33:#5 (Suppl), p. R39, 1990.Google Scholar
  483. 462.
    Hamdy H, McKendry RJR, Mierins E, Liver JA: Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial. Arthritis Rheum 30: 361–368, 1987.PubMedGoogle Scholar
  484. 463.
    Kvien TK, Hoyeraal HM, Sandstad B: Azathioprine versus placebo in patients with rheumatoid arthritis: A single center double blind comparative study. J Rheumatol 13: 118–123, 1986.PubMedGoogle Scholar
  485. 464.
    Silman AJ, Petrie J, Hazleman B, et al.: Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow up study. Ann Rheum Dis 47: 988–992, 1988.PubMedGoogle Scholar
  486. 465.
    Jeurissen MEC, Boerbooms AM Th, van de Putte LBA, Kruijsen MWM: Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis. Ann Rheum Dis 49: 25–27, 1990.PubMedGoogle Scholar
  487. 465a.
    Willkens RF, Urowitz MB, Stablein DM, et al.: Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. Arthritis Rheum 35: 849–856, 1992.PubMedGoogle Scholar
  488. 466.
    Singh G, Fries JF, Spitz P, Williams CA: Toxic effects of azathioprine in rheumatoid arthritis. Arthritis Rheum 32: 837–843, 1989.PubMedGoogle Scholar
  489. 467.
    Hardin JG: Cytotoxic-immunosuppressive drugs in the treatment of rheumatoid arthritis. Interm Med 8 (12): 123–137, 1987.Google Scholar
  490. 468.
    Baker GL, Kehl LE, Zee BC, et al.: Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 83: 1–9, 1987.PubMedGoogle Scholar
  491. 469.
    Parra A, Santos D, Cervantes C, et al.: Plasma gonadotropins and gonadal steroids in children treated with cyclophosphamide. J Pediatr 92: 117–124, 1978.PubMedGoogle Scholar
  492. 470.
    Puri HC, Campbell RA: Cyclophosphamide and malignancy. Lancet 1: 1306, 1977.PubMedGoogle Scholar
  493. 471.
    Scott DGI, Bacon PA: Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 76: 377–383, 1984.PubMedGoogle Scholar
  494. 472.
    Pedersen-Bjergaard J, Ersboll J, Hansen VL, et al.: Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin’s lymphoma. N Engl J Med 318: 1028–1032, 1988.PubMedGoogle Scholar
  495. 473.
    Arnold MH, Janssen B, Schrieber L, Brooks PM: Prospective pilot study of intravenous pulse cyclophosphamide therapy for refractory rheumatoid arthritis. Arthritis Rheum 32: 933–934, 1989.PubMedGoogle Scholar
  496. 474.
    Csuka ME, Carrera GF, McCarty DJ: Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study. JAMA 255: 2315–2319, 1986.PubMedGoogle Scholar
  497. 475.
    Palmer RG, Varonos S, Dore CJ, et al.: Chlorambucil induced chromosome damage in juvenile chronic arthritis. Arch Dis Child 60: 1008–1013, 1985.PubMedGoogle Scholar
  498. 476.
    Palmer RG, Ansell BM: Acute leukaemia related to chlorambucil therapy for juvenile chronic arthritis. Clin Exp Rheumatol 2: 81–83, 1984.PubMedGoogle Scholar
  499. 477.
    Callis L, Nieto J, Vila A, et al.: Chlorambucil treatment in minimal lesion nephrotic syndrome: A reappraisal of its gonadal toxicity. J Pediatr 97: 653–656, 1980.PubMedGoogle Scholar
  500. 478.
    Cohen AS, Rubinow A, Anderson JJ, et al.: Survival of patients with primary (AL) amyloidosis: colchicine-treated cases from 1978–1983 compared with cases seen in previous years (1961 to 1973). Am J Med 82: 1182–1190, 1987.PubMedGoogle Scholar
  501. 479.
    Dhillion V, Woo P, Isenberg D: Amyloidosis in the rheumatic diseases. Ann Rheum Dis 48: 696–701, 1989.Google Scholar
  502. 480.
    Shand N, Richardson B: Sandimmun (Cyclosporin A): mode of action and clinical results in rheumatoid arthritis. Scand J Rheumatol 76: 265–278, (Suppl) 1988.Google Scholar
  503. 481.
    Bjerkhoel F, Forre O: Cyclosporin treatment of a patient with severe systemic juvenile rheumatoid arthritis. Scand J Rheumatol 17: 483–486, 1988.PubMedGoogle Scholar
  504. 482.
    Weinblatt ME, Coblyn JS, Fraser PA, et al.: Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum 30: 11–17, 1987.PubMedGoogle Scholar
  505. 483.
    Dougados M, Amor B: Cyclosporin A in rheumatoid arthritis: preliminary clinical results of an open trial. Arthritis Rheum 30: 83–87, 1987.PubMedGoogle Scholar
  506. 484.
    Forre O, Bjerkhoel F, Salvesen CF, et al.: An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum 30: 88–92, 1987.PubMedGoogle Scholar
  507. 485.
    Dougados M, Awada H, Amor B: Cyclosporin in rheumatoid arthritis; a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 47: 127–133, 1988.PubMedGoogle Scholar
  508. 486.
    Yocum DE, Klippel JH, Wilder RL, et al.: Cyclosporine A in severe treatment-refractory rheumatoid arthritis. Ann Intern Med 109: 863–869, 1988.PubMedGoogle Scholar
  509. 487.
    Tugwell P, Bombardier C, Gent M, et al.: Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 335: 1051–5555, 1990.PubMedGoogle Scholar
  510. 488.
    Porter GA, Bennett WM, Sheps SG, et al.: Cyclosporine-associated hypertension. Arch Intern Med 150: 280–283, 1990.PubMedGoogle Scholar
  511. 489.
    Oates JA, Wood AJJ, Kahan BD: Drug Therapy. Cyclosporine. N Engl J Med 321:1725–1738, 1990 (see also Letters NEJM 322:1530–1531, 1990.)Google Scholar
  512. 490.
    Gupta AK, Rocher LL, Schmaltz SP, et al.: Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders. Arch Intern Med 151: 356–362, 1991.PubMedGoogle Scholar
  513. 491.
    Ost L: Effects of cyclosporin on prednisolone metabolism. Lancent 1: 451, 1984.Google Scholar
  514. 492.
    Whitington PF, Emond JC, Whitington SH, et al.: Small-bowel length and the dose of cyclosporine in children after liver transplantation. 322: 733–738, 1990.Google Scholar
  515. 493.
    van Rijthoven AWAM, Dukmans BAC, The DHSG, et al.: Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: A randomized, double blind, multicenter study. J Rheumatol 18: 815–820, 1991.PubMedGoogle Scholar
  516. 493a.
    Zijlmans JMJM, van Rijthoven AWAM, Kluin PM, et al. Epstein-Barr virus-associated lymphoma in a patient with rheumatoid arthritis treated with cyclosporine. NEJM 326: 13–63, 1992.Google Scholar
  517. 494.
    Symoens J, Schuermans Y: Levamisole. Clin Rheum Dis 6 (Suppl. 5): 603–629, 1979.Google Scholar
  518. 495.
    Horsely K, Petersen K, Bentsen KD, Engstrom-Laurent A, et al.: Serum amino terminal Type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months’ treatment with levamisole, penicillamine or azathioprine. Ann Rheum Dis 47: 116–126, 1988.Google Scholar
  519. 496.
    Editorial: Levamisole, a cautionary note. Lancet 2: 291–292, 1979.Google Scholar
  520. 497.
    Prieur AM, Buriot D, Lefur JM: Possible toxicity of levamisole in children with rheumatoid arthritis. J Pediatr 93: 304–305, 1978.PubMedGoogle Scholar
  521. 498.
    Wallace DJ, Goldfinger D, Lowe C, et al.: A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis. N Eng J Med 306: 1406, 1982.Google Scholar
  522. 499.
    Rothwell RS, David P, Gordon PA, et al.: A controlled study of plasma exchange in the treatment of severe rheumatoid arthritis. Arthritis Rheum 23: 785–790, 1980.PubMedGoogle Scholar
  523. 500.
    Karsh J, Klippel JH, Plotz PH, et al.: Lymphapheresis in rheumatoid arthritis: A randomized trial. Arthritis Rheum 24: 867–873, 1981.PubMedGoogle Scholar
  524. 501.
    Nickleson RW, Brewer EJ, Rossen RD, et al.: Plasma exchange in selected patients with juvenile rheumatoid arthritis. J Pediatr 98: 194–200, 1981.Google Scholar
  525. 502.
    Malaise MG, Hauwaert C, Franchimont P, et al.: Treatment of active rheumatoid arthritis with slow intravenous injections of thymopentin. A double-blind placebo-controlled randomized study. Lancet 1: 832–836, 1985.PubMedGoogle Scholar
  526. 503.
    Riskin WG, Gillings DB, Scarlett JA: Amiprilose hydrochloride for rheumatoid arthritis. Ann Intern Med 111: 455–465, 1989.PubMedGoogle Scholar
  527. 504.
    Cannon GW, Emkey RD, Denes A, et al.: Prospective two-year followup of recombinant interferon-gamma in rheumatoid arthritis. J Rheumatol 17: 304–310, 1990.PubMedGoogle Scholar
  528. 505.
    Breedveld FC, Dukmans BAC, Mattie H: Minocycline treatment for rheumatoid arthritis: an open dose finding study. J Rheumatol 17: 43–46, 1990.PubMedGoogle Scholar
  529. 506.
    Kremer JM, Jubiz W, Michalek A, et al.: Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. Ann Intern Med 106: 497–503, 1987.PubMedGoogle Scholar
  530. 507.
    Szobor A: Benefit of thymectomy in immune disease other than myasthenia. Lancet 1: 277–278, 1984.PubMedGoogle Scholar
  531. 508.
    van Zeben D, Hazes JMW, Vandenbroucke JP, et al.: Diminished incidence of severe rheumatoid arthritis associated with oral contraceptive use. Arthritis Rheum 33: 1462–1465, 1990.PubMedGoogle Scholar
  532. 509.
    Pritchard MH, Munro J: Successful treatment of Juvenile Chronic Arthritis with a specific antiviral agent. Br J Rheumatol 28: 521–524, 1989.PubMedGoogle Scholar
  533. 510.
    Malawista SE, Trock DH, Edelson RL: Treatment of rheumatoid arthritis by extracorporeal photochemotherapy. A pilot study. Arthritis Rheum 34: 646–654, 1991.PubMedGoogle Scholar
  534. 511.
    Southwood TR, Malleson PN, Roberts-Thomson PJ, Mahy M: Unconventional remedies used for patients with juvenile arthritis. Pediatrics 85: 150–154, 1990.PubMedGoogle Scholar
  535. 512.
    Jacobs JC: Arthritis as a manifestation of connective tissue diseases. In Moore TD (ed.) Arthritis in Childhood. Report of the 80th Ross Conference on Pediatric Research. Xanadu, Bahamas, December 2–5, 1979. Ross Laboratories, Columbus, OH, 1981, pp. 18–23.Google Scholar
  536. 513.
    Suciu-Foca N, Jacobs J, Godfrey M, et al.: HLA-DR5 in juvenile rheumatoid arthritis confined to a few joints. Lancet 2: 40, 1980.PubMedGoogle Scholar
  537. 514.
    Myers LK, Ball EJ, Nunez G, et al.: HLA-D region epitopes associated with juvenile arthritis. Recognition by alloreactive T call clones and alloantisera. Arthritis Rheum 30: 744–751, 1987.PubMedGoogle Scholar
  538. 515.
    Streekawkas AJ, Collery RT, McDowell J, et al.: Direct evidence for loss of human suppressor cells during active autoimmune disease. Proc Natl Acad Sci 75: 5150–5154, 1978.Google Scholar
  539. 516.
    Vostrejs M, Hollister R: Muscle atrophy and leg length discrepancies in pauciarticular juvenile rheumatoid arthritis. Am J Dis Child 142: 343–345, 1988.PubMedGoogle Scholar
  540. 517.
    Kanski JJ: Screening for uveitis in juvenile chronic arthritis. Br J Opthalmol 73: 225–228, 1989.Google Scholar
  541. 518.
    Fernandez-Vina MA, Fink CW, Stastny P. HLA antigens in juvenile arthritis. Arthritis Rheum 33: 1787–1784, 1990.PubMedGoogle Scholar
  542. 519.
    Earley A, Cuttica RJ, McCullough CM, Ansell BM: Triamcinolone into the knee joint in juvenile chronic arthritis. Clin Exp Rheumatol 6: 153–155, 1988.PubMedGoogle Scholar
  543. 520.
    Balogh K: The histologic appearance of corticosteroid injection sites. Arch Pathol Lab Med 110: 1168–1172, 1986.PubMedGoogle Scholar
  544. 521.
    Gilsanz V, Bernstein BH: Joint calcification following intraarticular corticosteroid therapy. Radiology 151: 647–649, 1984.PubMedGoogle Scholar
  545. 522.
    Sparling M, Malleson P, Wood B, Petty R: Radiographic followup of joints injected with triamcinolone hexacetonide for the management of childhood arthritis. Arthritis Rheum 33: 821–826, 1990.PubMedGoogle Scholar
  546. 523.
    Allen RC, Gross KR, Malleson PN, et al.: Intraarticular triamcinolone hexacetonide in the management of chronic arthritis in children. Arthritis Rheum 29: 997–1001, 1986.PubMedGoogle Scholar
  547. 524.
    Huskisson EC: Intraarticular and soft-tissue injections. In Hart FD (ed.) Drug Treatment of the Rheumatic Diseases Williams and Wilkins, Sydney, 1987, pp. 111–116.Google Scholar
  548. 525.
    Montgomery SC, Campbell J: Septic arthritis following arthroscopy and intraarticular steroids. J Bone Joint Surg 71–8: 540, 1989.Google Scholar
  549. 526.
    Hutchinson J: On a peculiar form of iritis which occurs in the children of gouty parents. Lancet 1–3, 1873.Google Scholar
  550. 527.
    Calabro JJ, Marchesano JM, Parrino GR: Juvenile rheumatoid arthritis: longterm management and prognosis. J Musculoskeletal Med pp. 17–32, January 1989.Google Scholar
  551. 528.
    Sherry DD, Mellins ED, Wedgwood RJ: Decreasing severity of chronic uveitis in children with pauciarticular arthritis. Am J Dis Child 145: 1026–1028. 1991.PubMedGoogle Scholar
  552. 529.
    Spalter HF: The visual prognosis in juvenile rheumatoid arthritis. Trans Am Ophthalmol Soc 73: 554–570, 1975.PubMedGoogle Scholar
  553. 530.
    Kanski JJ: Uveitis in juvenile chronic arthritis: incidence, clinical features and prognosis. Eye 2: 641–645, 1988.PubMedGoogle Scholar
  554. 531.
    Melin-Aldana H, Giannini EH, Taylor J, et al.: Human leukocyte antigenDRBI*1104 in the chronic iridocyclitis of pauciarticular juvenile rheumatoid arthritis. J Pediatr 121: 56–60, 1992.PubMedGoogle Scholar
  555. 532.
    Rosenberg AM, Oen KG: The relationship between ocular and articular disease activity in children with juvenile rheumatoid arthritis and associated uveitis. Arthritis Rheum 29: 797–800, 1986.PubMedGoogle Scholar
  556. 533.
    Olson NY, Lindsley CB, Godfrey WA: Nonsteriodal anti-inflammatory drug therapy in chronic childhood iridocyclitis. Am J Dis Child 142: 1289–1292, 1988.PubMedGoogle Scholar
  557. 533a.
    Dougados M, Berenbaum F, Maetzel A, et al.: The use of sulfasalazine for the prevention of attacks of acute anterior uveitis associated with spondyloarthropathy. Arthritis Rheum 34: S195, 1991.Google Scholar
  558. 534.
    Chylack LT, Dueker DK, Pihlaja DJ: Ocular manifestations of juvenile rheumatoid arthritis: Pathology, florescein iris angiography, and patient care patterns. In Miller JJ III (ed.) Juvenile Rheumatoid Arthritis. PSG, Littleton, MA, 1979.Google Scholar
  559. 535.
    Johns KJ, Chandra SR: Visual loss following intranasal corticosteroid injection. JAMA 261: 2413, 1989.PubMedGoogle Scholar
  560. 536.
    Merrimam JC, Chylack LT, Albert DM: Early-onset pauciarticular juvenile rheumatoid arthritis: a histopathologic study. Arch Ophthalmol 101: 1085–1092, 1983.Google Scholar
  561. 537.
    Wolf MD, Lichter PR, Ragsdale CG: Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Opththalmology 94: 1242–1248, 1987.Google Scholar
  562. 538.
    Herman DC: Endogenous Uveitis: Current concepts of treatment. Mayo Clin Proc 65: 671–683, 1990.PubMedGoogle Scholar
  563. 539.
    Palmer RG, Kanski JJ, Ansell BM: Chlorambucil in the treatment of intractable uveitis associated with juvenile chronic arthritis. J Rheumatol 12: 967–970, 1985.PubMedGoogle Scholar
  564. 540.
    Palestine AG, Austin HA III, Balow JE, et al.: Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 314: 1293–1298, 1986.PubMedGoogle Scholar
  565. Vawter RL, Macsai M, Fakadej A, et al. Methotrexate for inflammatory eye disease. Arthritis rheum 35 #5S: R12, 1992.Google Scholar
  566. 540b.
    b.Bridges AJ, Burns RP. Acute iritis associated with primary Sjogren’s syndrome and high-titer anti-SS-A/Ro and anti-SS-B-/La antibodies. Athritis Rheum 35: 560–563, 1992.Google Scholar
  567. 541.
    Kanski JJ: Juvenile arthritis and uveitis. Sury Ophthalmol 34: 253–267, 1990.Google Scholar
  568. 542.
    Kanski JJ, Shun-Shin GA: Systemic uveitis syndromes in childhood: an analysis of 340 cases. Ophthamology 91: 1247–1252, 1984.Google Scholar
  569. 543.
    Praeger DL, Schneider HA, Sakowski AD, Jacobs JC: Kelman procedure in the treatment of complicated cataract of uveitis of Still’s disease. Trans Ophthalmol Soc UK 96: 168–172, 1976.PubMedGoogle Scholar
  570. 544.
    Flynn HW, Davis JL, Culbertson WW, Pars plana lensectomy and vitrectomy for complicated cataracts in juvenile rheumatoid arthritis. Ophthalmology 95: 1114–1119, 1988.PubMedGoogle Scholar
  571. 545.
    Diamond JG, Kaplan HJ: Lensectomy and vitrectomy for complicated cataract secondary to uveitis. Arch Ophthalmol 96: 1798–1804, 1978.PubMedGoogle Scholar
  572. 546.
    Lambert JR, Ansell BM, Stephenson E, et al.: Psoriatic arthritis in childhood. Clin Rheum Dis 2: 339–352, 1976.Google Scholar
  573. 547.
    Sills EM: Psoriatic arthritis in childhood. Johns Hopkins Med J 146: 49–53, 1980.PubMedGoogle Scholar
  574. 548.
    Shore A, Ansell BM: Juvenile psoriatic arthritis-an analysis of 60 cases. J Pediatr 100: 529–535, 1982.PubMedGoogle Scholar
  575. 549.
    Southwood TR, Petty RS, Malleson PN, et al.: Psoriatic arthritis in children. Arthritis Rheum 32: 1007–1013, 1989.PubMedGoogle Scholar
  576. 550.
    Gerber J, Espinoza LR (eds.) Psoriatic Arthritis. Grune and Stratton, Orlando, 1985.Google Scholar
  577. 551.
    Seideman P, Fjellner B, Johannesson A: Psoriatic arthritis treated with oral colchicine. J Rheumatol 14: 777–779, 1987.PubMedGoogle Scholar
  578. 552.
    Steinsson K, Jonsdottir I, Valdimarsson H: Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis 49: 603–606, 1990.PubMedGoogle Scholar
  579. 553.
    Huckins D, Felson DT, Holick M: Treatment of psoriatic arthritis with oral 1, 25-dihydroxyvitamin D3: A pilot study. Arthritis Rheum 33: 1723–1727, 1990.Google Scholar
  580. 554.
    Ellis CN, Fradin MS, Messana JM, et al.: Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324:277–294, 1991 (see also correspondence pp. 1894–1985).Google Scholar
  581. 555.
    Randall T: Cyclosporine: vital in today’s transplantation, but questions remain about tomorrow. JAMA 264: 1794–1797, 1990.PubMedGoogle Scholar
  582. 556.
    van Rijthoven AWAM, Dijkmans BAC, Goei The HS, et al.: Long-term cyclosporine therapy in rheumatoid arthritis. J Rheumatol 18: 19–23, 1991.PubMedGoogle Scholar
  583. 557.
    Gay RE, Palmoski MJ, Brandt KD, Gay S: Aspirin causes in vivo synthesis of type I collagen by atrophic articular cartilage. Arthritis Rheum 26: 1231–1236, 1983.PubMedGoogle Scholar
  584. 558.
    Williams PE: Effect of intermittent stretch on imobilized muscle. Ann Rheum Dis 47: 1014–1016, 1988.PubMedGoogle Scholar
  585. 559.
    Hinojosa J, Anderson J, Strauch C: Pediatric occupational therapy in the home. Am J Occup Ther 42: 17–22, 1988.PubMedGoogle Scholar
  586. 560.
    Gallino L, Pountain G, Mitchell N, Ansell BM: Developmental aspects of the hip in juvenile chronic arthritis. A radiologic assessment. Scand J Rhematol 13: 310–318, 1984.Google Scholar
  587. 561.
    Vostrejs M, Hollister JR: Muscle atrophy and leg length discrepancies in pauciarticular juvenile rheumatoid arthritis. Am J Dis Child 142: 343–345, 1988.PubMedGoogle Scholar
  588. 562.
    Editorial: joint injury and muscle weakness. Lancet 2:381–382, 1984.Google Scholar
  589. 563.
    Jacobsen ST, Levinson JE, Crawford AH: Late results of synovectomy in juvenile rheumatoid arthritis. J Bone Joint Surg 67-A: 8–15, 1985.Google Scholar
  590. 564.
    Rydholm U, Elborgh R, Ranstam J, et al.: Synovectomy of the knee in juvenile chronic arthritis: a retrospective, consecutive follow-up study. J Bone Joint Surg 68B: 223–228, 1986.Google Scholar
  591. 564a.
    Ovregard T, Hoyeraal HM, Pahle JA, Larsen S. A three-year retrospective study of synovectomies in children. Clin Orthop Rel Res 259: 76–82, 1990.Google Scholar
  592. 565.
    Combe B, Krause E, Sany J: Treatment of chronic knee-synovitis with arthroscopic synovectomy after failure of intraarticular injection of radionuclide. Arthritis Rheum 32: 10–14, 1989.PubMedGoogle Scholar
  593. 566.
    Mogensen B, Brattstrom H, Svantesson H, Lidgren L: Soft tissue release of the hip in juvenile chronic arthritis. Scand J Rheumatol 12: 17–20, 1983.PubMedGoogle Scholar
  594. 567.
    Scott RD, Sarokhan AJ, Dalziel R: Total hip and total knee arthroplasty in juvenile rheumatoid arthritis. Clin Orthop 182: 90–97, 1984.PubMedGoogle Scholar
  595. 568.
    Kunec JR: Total hip replacement in patients under thirty-five years of age. Orthopedics 6: 1432–1434, 1983.Google Scholar
  596. 569.
    Ruddlesdin C, Ansell BM, Arden GP, Swann M: Total hip replacement in children with juvenile chronic arthritis. J Bone Joint Surg 68B: 218–222, 1986.Google Scholar
  597. 570.
    Arthritis of the hip in children. Lancet 2: 260, 1986.Google Scholar
  598. 571.
    Gudmundsson GH, Harving S, Pilgaard S: The Charnley total hip arthroplasty in juvenile rheumatoid arthritis patients. Orthopedics 12: 385–388, 1989.PubMedGoogle Scholar
  599. 572.
    Dossick PH, England S, Huo M, et al.: Total hip replacement in juvenile rheumatoid arthritis. Arthritis Rheum 33 #5(Suppl): R40, 1990.Google Scholar
  600. 573.
    Sarokhan AJ, Scott RD, Thomas WH, et al.: Total knee arthroplasty in juvenile rheumatoid arthritis. J Bone Joint Surg 65A: 1071–1080, 1983.PubMedGoogle Scholar
  601. 574.
    Nicholas SA, Figgie MP, Alexiades MM, et al.: Total knee replacement in juvenile rheumatoid arthritis. Arthritis Rheum 33 #5(Suppl): R40, 1990.Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Jerry C. Jacobs
    • 1
  1. 1.Section of Pediatric Rheumatology and the Regional Arthritis Program (RAP-4-Kids)Columbia-Presbyterian Medical CenterNew YorkUSA

Personalised recommendations